

Free Executive Summary

Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII – Phase 2



Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation, National Research Council

ISBN: 0-309-09156-X, 750 pages, 8 1/2 x 11, paperback (2005)

This free executive summary is provided by the National Academies as part of our mission to educate the world on issues of science, engineering, and health. If you are interested in reading the full book, please visit us online at <http://www.nap.edu/catalog/11340.html>. You may browse and search the full, authoritative version for free; you may also purchase a print or electronic version of the book. If you have questions or just want more information about the books published by the National Academies Press, please contact our customer service department toll-free at 888-624-8373.

This executive summary plus thousands more available at www.nap.edu.

Copyright 2004 © National Academy of Sciences. Permission is granted for this material to be shared for noncommercial, educational purposes, provided that this notice appears on the reproduced materials, the Web address of the online, full authoritative version is retained, and copies are not altered. To disseminate otherwise or to republish requires written permission from the National Academies Press.

Units Used to Express Radiation Dose

Radiation exposures are measured in terms of the quantity *absorbed dose*, which equals the ratio of energy imparted to the mass of the exposed body or organ. The unit of absorbed dose is joule/kilogram (J/kg). For convenience this unit has been given the special name gray (Gy).

Ionizing radiation can consist of electromagnetic radiation, such as x rays or gamma rays (γ rays), or of sub-atomic particles, such as protons, neutrons, and α particles. X and γ rays are said to be sparsely ionizing, because they produce fast electrons which cause only a few dozen ionizations when they traverse a cell. Because the rate of energy transfer is called *linear energy transfer (LET)*, they are also termed *low-LET* radiation; *low-LET* radiations are the subject of this report. In contrast, the heavier particles are termed *high-LET* radiations, because they transfer more energy per unit length as they traverse the cell.

Since the high-LET radiations are capable of causing more damage per unit absorbed dose, a weighted quantity, *equivalent dose*, or its average over all organs, *effective dose*, is used for radiation protection purposes. For low-LET radiations, *equivalent dose* equals *absorbed dose*. For high-LET radiation – such as neutrons, α particles or heavier ion particles – *equivalent dose* or *effective dose* equals the *absorbed dose* multiplied by a factor – the *quality factor* or the *radiation weighting factor* (see report glossary) – to account for their increased effectiveness. Since the weighting factor for radiation quality is dimensionless, the unit of *equivalent dose* is also J/kg. However, to avoid confusion between the two dose quantities, the special name sievert (Sv) has been introduced for use with *equivalent dose* and *effective dose*.

Although the BEIR VII report is about low-LET radiation, the committee had to consider information derived from complex exposures – especially from the A-bomb radiation – that include in addition to the low-LET radiation also a high-LET contribution. A *weighted dose*, with a weight factor that differs from the quality factor and the radiation weighting factor is employed in these computations. The symbol Sv for the unit is used likewise with this quantity.

Whenever the nature of the quantity is apparent from the context the term *dose* is used equally in this report for *absorbed dose*, *equivalent dose*, *effective dose*, and *weighted dose*. With regard to risk assessment, reference is usually to the *equivalent dose* to specified organs or to the *effective dose*. The symbol Sv for the unit is then used, although absorbed dose and equivalent dose are equal for low-LET radiation. In experimental radiation biology and in radiotherapy exact specification of absorbed dose is required and the dose values are frequently larger than in radiation protection considerations. With reference to those fields, therefore, use is made of absorbed dose and the symbol Gy for the unit.

The Public Summary refers to radiation protection, and the dose unit, therefore, is given as Sv throughout this section (for a more complete description of the various dose quantities and units used in the BEIR VII report, see the report glossary and the Units of Dose Table below).

Units of Dose

Unit ^a	Symbol	Conversion Factors
becquerel (SI)	Bq	1 disintegration/s = 2.7×10^{-11} Ci
curie	Ci	3.7×10^{10} disintegrations/s = 3.7×10^{10} Bq
gray (SI)	Gy	1 J/kg = 100 rad
rad	rad	0.01 Gy = 100 erg/g
sievert (SI)	Sv	1 J/kg = 100 rem
rem	rem	0.01 Sv

^a International Units are designated SI.

Note: Equivalent dose equals absorbed dose times Q (quality factor). Gray is the special name of the unit J/kg to be used with absorbed dose; sievert is the special name of the unit J/kg to be used with equivalent dose

Public Summary

INTRODUCTION

The health effects of low levels of ionizing radiation are important to understand. Ionizing radiation--the sort found in x rays or gamma rays¹--is defined as radiation that has sufficient energy to displace electrons from molecules. Free electrons, in turn, can damage human cells. One challenge to understanding the health effects of radiation is that there is no general property that makes the effects of man-made radiation different from those of naturally occurring radiation. Still another difficulty is that of distinguishing cancers that occur because of radiation exposure from cancers that occur because of other causes. These facts are just some of the many that make it difficult to characterize the effects of ionizing radiation at low levels.

Despite these challenges, there is a great deal about this topic that is well understood. Specifically, there is substantial evidence that exposure to high levels of ionizing radiation can cause illness or death. Further, scientists have long known that, in addition to cancer, ionizing radiation at high doses causes mental retardation in the children of mothers exposed to radiation during pregnancy. Recently, data from the atomic bomb survivors suggest high doses are also connected to other health effects such as heart disease and stroke.

Because ionizing radiation is a threat to health, it has been studied extensively. This report is the seventh in a series of publications from the National Academies concerning radiation health effects called the Biological Effects of Ionizing Radiation (BEIR) reports. This report, BEIR VII, focuses on the health effects of low levels of low linear energy transfer (LET) ionizing radiation. Low-LET radiation deposits less energy in the cell along the radiation path and is considered less destructive per radiation track than high-LET radiation. Examples of low-LET radiation, the subject of this report, include x rays and γ rays (gamma rays). Health effects of concern include cancer, hereditary diseases, and other effects, such as heart disease.

In this summary, we describe:

- how ionizing radiation was discovered
- how ionizing radiation is detected
- units used to describe radiation dose
- what we mean by low doses of ionizing radiation
- exposure from natural "background" radiation
- contribution of man-made radiation to public exposure

¹ x rays are man-made and generated by machines whereas gamma rays occur from unstable atomic nuclei. People are continuously exposed to gamma rays from naturally occurring elements in the earth and [outer space](#).

Prepublication copy Uncorrected Proofs

- scenarios illustrating how people might be exposed to ionizing radiation above background levels
- evidence for adverse health effects such as cancer and hereditary disease
- the BEIR VII risk models
- what bodies of research the committee reviewed
- why the committee has not accepted the view that low levels of radiation might be substantially more or less harmful than expected from the model used in this BEIR report.
- the committee's conclusions

HOW IONIZING RADIATION WAS DISCOVERED

Low levels of ionizing radiation cannot be seen or felt, so the fact that people are constantly exposed to radiation is not usually apparent. Scientists began to detect the presence of ionizing radiation in the 1890s². In 1895, Wilhelm Conrad Roentgen was investigating an electrical discharge generated in a paper-wrapped glass tube from which most of the air had been evacuated. The free electrons generated in the “vacuum tube,” which were then called cathode rays, were in themselves a form of radiation. Roentgen noted that when the electrons were being generated, a fluorescent screen on a near-by table began to glow. Roentgen theorized that invisible emissions from the cathode-ray tube were causing the fluorescent screen to glow, and he termed these invisible emissions x rays. The electrons produced by the electrical discharge had themselves produced another form of radiation, x rays. The next major discovery occurred when Henri Becquerel noted that unexposed photographic plates stored in a drawer with uranium ore were fogged. He concluded that the photographic plate fogging was from an invisible emission emanating from the uranium atoms and their decay products. This turned out to be naturally-occurring radiation emanating from the uranium. Marie and Pierre Curie went on to purify radium from uranium ore in Becquerel’s laboratory, and in subsequent years, many other forms of radiation including neutrons, protons and other particles were discovered. Thus, within a period of several years in the 1890s, man-made and naturally-occurring radiation were discovered.

Roentgen’s discovery of x rays resulted in the eventual invention of x ray machines used to image structures in the human body and to treat health conditions. Adverse health effects of high levels of ionizing radiation exposure became apparent shortly after these initial discoveries. High doses to radiation workers would redden the skin (erythema), and this rough measure of radiation exposure was called the “skin erythema dose”. The use of very large doses, primitive dosimetry (dose measurement), such as the “skin erythema” dose, and the fact that many of these early machines were not well shielded, led to high radiation exposures both to the patients and to the persons administering the treatments. The development of chronic, slow-healing, skin lesions on the hands of early radiologists and their assistants resulted in the loss of extremities in some cases. Those incidents were

² Health Physics Society Website: <http://www.hps.org/> September 2004. Figures in Radiation History.

some of the first indications that radiation delivered at high doses could have serious health consequences. Subsequent studies in recent years have shown that the early radiologists had a higher mortality rate than other health workers. This increased mortality rate is not seen in radiologists working in later years, presumably due to vastly improved safety conditions resulting in much lower doses to the radiologists.

The early indications of health effects after high radiation exposures are too many to chronicle in this Public Summary, but we note one frequently cited example. In 1896, Thomas Edison developed a fluoroscope that consisted of a tapered box with a calcium tungstate screen and a viewing port by which physicians could view x ray images. During the course of these investigations with x rays, Clarence Dally, one of Edison's assistants, developed a degenerative skin disease, which progressed into a carcinoma. In 1904, Dally succumbed to his injuries in what may have been the first death associated with man-made ionizing radiation in the United States. Edison halted all his x ray research noting "the x rays had affected poisonously my assistant, Mr. Dally²...". Today, radiation is one of the most thoroughly studied potential hazards to humans, and regulatory standards have become increasingly strict over the years in an effort to protect human health.

HOW IONIZING RADIATION IS DETECTED

The detection of ionizing radiation has greatly improved since the days of Roentgen, Becquerel, and the Curies. Ionizations can be accurately detected by Geiger counters and other devices. Because the efficiency of the detector is known, one can determine not only the location of the radiation, but also the amount of radiation that is present. Other, more sophisticated, detectors can evaluate the "signature" energy spectrum of some radiations and thus identify the type of radiation.

UNITS USED TO DESCRIBE RADIATION DOSE

Ionizing radiation can be in the form of electromagnetic radiation, such as x rays or γ rays, or in the form of sub-atomic particles, such as protons, neutrons, alpha particles, and beta particles. Radiation units can be confusing. Radiation is usually measured in dose units called Gray (Gy) or Sievert (Sv), which are measures of energy deposited in living tissue. X and γ rays are said to have low linear energy transfer (low-LET). Low-LET radiations produce ionizations sparsely throughout a cell; in contrast, high-LET radiations transfer more energy per unit length as they traverse the cell and are more destructive per unit length.

Although the BEIR VII report is about low-LET radiation, the committee has considered some information derived from complex exposures that include radiation from high-LET and low-LET sources. High-LET or mixed radiations (radiation from high-LET and low-LET sources) are often described in units known as sievert. Units for low-LET radiation can be given in Sievert or Gray. For simplicity, all dose units in the Public Summary are reported in Sievert (Sv). For a more complete description of the various units of dose used in the BEIR VII report, see the section "Units Used to Express Radiation

Dose” section that precedes the Public Summary as well as the report glossary (Gray, Sievert, Units).

WHAT WE MEAN BY LOW DOSES OF IONIZING RADIATION

For this report, the Committee has defined low dose as doses in the range of near zero up to about 100 mSv (0.1 Sv) of low-LET radiation. The committee has placed emphasis on the lowest doses where relevant data are available. The annual worldwide background exposure from natural sources of low-LET radiation is about one mSv.

EXPOSURE FROM NATURAL "BACKGROUND" RADIATION

Human beings are exposed to natural "background" radiation every day from the ground, building materials, air, food, the universe, and even elements in their own bodies. In the United States, the majority of exposure to natural "background" ionizing radiation comes from exposure to radon gas and its decay products. Radon is a colorless, odorless gas that emanates from the earth and that, along with its decay products, emits a mixture of high- and low-LET radiations. Radon can be hazardous when accumulated in underground areas such as poorly ventilated basements. A previous BEIR report, Biological Effects of Ionizing Radiation VI, reported on the health effects of radon, and therefore these health effects are not discussed in this report. Average annual exposures worldwide to natural radiation sources (both high- and low-LET) would generally be expected to be in the range of 1-10 mSv with 2.4 mSv being the present estimate of the central value³. Of this amount, about one-half (1.2 mSv per year) is from radon and its decay products. Average annual background exposures in the United States are slightly higher (3.0 mSv) due in part to higher average radon levels. After radon, the next largest percentage of natural ionizing radiation exposure comes from cosmic rays, followed by terrestrial sources, and "internal" emissions. Cosmic rays are particles that travel through the universe. The sun is a source of some of these particles. Others come from exploding stars called supernovas.

The amount of terrestrial radiation from rocks and soils varies geographically. For example, in the United States, the average person living in Florida is exposed to about 2 mSv a year from terrestrial radiation whereas a person living in northeast Washington State might be exposed to 17 mSv a year⁴. Much of this variation is due to differences in radon levels. "Internal" emissions come from radioactive isotopes in food and water and from the human body itself. Exposures from eating and drinking are due in part to the uranium and thorium series of radioisotopes present in foods and drinking water⁵. An

³ UNSCEAR 2000: Sources and Effects of Ionizing Radiation Volume 1: Sources, United Nations, New York, Table 31, p40.

⁴ NCRP Report No. 93

⁵ UNSCEAR Sources and Effects of Ionizing Radiation. 2000 Report to the General Assembly, with scientific annexes. United Nations, New York.

Prepublication copy Uncorrected Proofs

example of a radioisotope moving through the food chain would be carbon 14 (^{14}C), a substance found in all living things. ^{14}C is created when cosmic rays collide with nitrogen atoms. ^{14}C combines with oxygen, creating carbon dioxide gas. Plants absorb carbon dioxide during photosynthesis, and animals feed on plants. In those ways, ^{14}C accumulates in the food chain and contributes to the internal background dose from ionizing radiation.

As mentioned previously, possible health effects of low-dose, low-LET radiation are the focus of the BEIR VII report. Because of the "mixed" nature of many radiation sources, it is difficult to estimate precisely the percentage of natural background radiation that is low-LET. Figure PS-1 illustrates the approximate sources and relative amounts of high-LET and low-LET radiations that comprise the natural "background" exposure worldwide. The chart illustrates the relative contributions of three natural sources of high-LET radiation and three natural sources of low-LET radiation to the global population exposure. The smaller, detached segment of the pie chart represents the relative contribution of low-LET radiation sources to the annual background exposure. The total average annual population exposure worldwide due to low-LET radiation would generally be expected to be in the range of 0.2–1.0 mSv with 0.9 mSv being the present estimate of the central value.




FIGURE PS-1. Sources of global "background" radiation. The pie chart above shows the relative world-wide percentage of all sources of natural "background" radiation (low- and high-LET). Because the BEIR VII report evaluates the health effects of low-LET radiation, we have separated the low-LET portion of the pie chart to illustrate the relative contributions of the three major sources of low-LET radiation exposure.

CONTRIBUTION OF MAN-MADE RADIATION TO PUBLIC EXPOSURE

In addition to natural "background" radiation, people are also exposed to low- and high-LET radiation from man-made sources such as x ray equipment and radioactive materials used in medicine, research, and industry. A 1987 study⁶ of ionizing radiation exposure to the population of the United States estimated that natural "background" radiation comprised 82% of the annual U.S. population exposure while man-made sources contributed 18% of the exposure (see figure PS-2, pie chart in the lower left portion of the figure).

⁶ NCRP (National Council on Radiation Protection). 1987. Ionizing Radiation Exposure of the Population of the United States. Washington, DC. National Council on Radiation Protection and Measurements, No.93.




FIGURE PS-2. The pie chart in the lower left portion of the figure shows the contribution of man-made radiation sources (18%) relative to natural "background" radiation (82%) exposure of the population of the United States. Sources of man-made radiation are detailed in the pie chart in the upper right portion of the page.

In figure PS-2 the man-made radiation component (pie chart in upper right portion of the figure) shows the relative contributions of the various types of man-made radiation to the US population⁷. Medical x rays and nuclear medicine account for about 79% of the

⁷ NCRP (National Council on Radiation Protection). 1987. Ionizing Radiation Exposure of the Population of the United States. Washington, DC. National Council on Radiation Protection and Measurements, No.93.

man-made radiation exposure in the United States. Elements in consumer products such as tobacco, the domestic water supply, building materials, and, to a lesser extent, smoke detectors, televisions, and computer screens, account for another 16%. Occupational exposures, fallout, and the nuclear fuel cycle comprise less than 5% of the man-made component. Additional small amounts of exposure from background and man-made radiation come from activities such as traveling by jet aircraft (due to cosmic radiation—add 0.01 mSv for each 1000 miles traveled), living near a coal-fired power plant (from plant emissions—add 0.0003 mSv), being near x ray luggage inspection scanners (add 0.00002 mSv), or living within 50 miles of a nuclear power plant (add 0.00009 mSv)⁸.

There are many ways in which an individual's exposure to ionizing radiation could vary from the averages. Factors that might increase exposure to ionizing radiation include (a) increased uses of radiation for medical purposes, (b) occupational exposure to radiation, and (c) smoking tobacco products⁹. Factors that might decrease radiation exposure include living at lower altitudes (less cosmic radiation) and living and working in the higher floors of a building (less radon).

SCENARIOS ILLUSTRATING HOW PEOPLE MIGHT BE EXPOSED TO IONIZING RADIATION ABOVE BACKGROUND LEVELS

In this section we provide three scenarios illustrating how some people might be exposed to ionizing radiation above background levels. These examples are for illustration purposes in the Public Summary only and are not meant to be inclusive.

Whole Body Scans

There is growing use of whole body scanning by computed tomography (CT) as a way of screening for early signs of disease among asymptomatic adults¹⁰. CT examinations result in higher organ doses of radiation than conventional single-film x rays. This is because, in CT, scanners rotate around the body, taking a series of cross sectional x rays. A computer compiles these x ray slices to produce a three-dimensional portrait. According to Brenner and Elliston (2004), who estimated both radiation dose and risks from such procedures, a single full-body scan results in a mean effective radiation dose of 12 mSv.¹¹ As these authors write, “to put this (dose) in perspective, a typical mammogram . . . has an effective dose of 0.13 mSv—a factor of almost 100 times less.” According to Brenner and Elliston's calculations, “a 45-year-old adult who plans to undergo 30 annual full-body CT examinations would potentially accrue an estimated lifetime cancer mortality

⁸ National Council of Radiation Protection and Measurement Reports #92-95 and #100.

⁹ National Council on Radiation Protection and Measurements. Radiation exposure of the US population from consumer products and miscellaneous sources. Bethesda, MD: NCRP Report No. 95; 1987.

¹⁰ Full-Body CT Scans: What You Need to Know (brochure). U. S. Department of Health and Human Services Publication No. (FDA) 03-001 (March 2003). Accessed via the web at www.fda.gov/cdrh/ct. Web site title is “Whole Body Scanning: Using Computed Tomography (CT)”, December 2004.

¹¹ Brenner, D. J., Elliston, C. D. 2004. Estimated radiation risks potentially associated with full-body CT screening. *Radiology*: 232: 735-738.

risk of 1.9% (almost 1 in 50)... Correspondingly, a 60-year-old who plans to undergo 15 annual full-body CT examinations would potentially accrue an estimated lifetime cancer mortality risk of one in 220¹². Citing a National Vital Statistics Report, Brenner and Elliston note that, for comparison, “the lifetime odds that an individual born in the United States in 1999 will die in a traffic accident are estimated to be one in 77¹².” Further information on whole body scans is available from the U. S. Food and Drug Administration’s website¹³.

CT Scans Used in Diagnostic Procedures

The use of CT scans in adults experiencing symptoms of illness or injury is widely accepted, and CT scan use has increased substantially in the last several decades. The BEIR VII committee recommends that, in the interest of radiological protection, there be follow-up studies of cohorts of persons receiving CT scans, especially children. In addition, the Committee recommends studies of infants who experience diagnostic radiation exposure related to cardiac catheterization and of premature infants who are monitored with repeated x rays for pulmonary development.

Working Near Ionizing Radiation

People who work at medical facilities, in mining, milling, or with nuclear weapons are required to take steps to protect themselves from occupational exposures to radiation. The maximum amount radiation workers are allowed to receive in connection with their occupations is regulated. In general these limits are 50 mSv/year to the whole body with larger amounts allowed to the extremities. The exposure limits for a pregnant worker, once pregnancy is declared, are more stringent. In practice the guidelines call for limiting exposures to as low as is reasonably achievable.

Combined analyses of data from nuclear workers offer an opportunity to increase the sensitivity of such studies and to provide direct estimates of the effects of long-term low-dose low-LET radiation. It should be noted however, that even with the increased sensitivity the combined analyses are compatible with a range of possibilities, from a reduction of risk at low doses to risks twice those upon which current radiation protection recommendations are based.

Veterans Exposed to Radiation through Weapons Testing

¹² Hoyert, D. L., Arias, E., Smith, B. L., Murphy, S. L., Kochanek, K. D. 2001. Deaths: final data for 1999. National Vital Statistics Report U S A: 49: 1-113.

¹³ Full-Body CT Scans: What You Need to Know (brochure). U. S. Department of Health and Human Services Publication No. (FDA) 03-001 (March 2003). Accessed via the web at www.fda.gov/cdrh/ct. Web site title is “Whole Body Scanning: Using Computed Tomography (CT)”, June, 2005.

An example of man-made radiation exposures experienced by large numbers of people in the past is the experience of the U.S. atomic veterans during and after WW II. From 1945 – 1962 about 210,000 military and civilian personnel were directly exposed at a distance to above-ground atomic bomb tests (about 200 atmospheric weapons tests were conducted in this time span)¹⁴. In general, these exercises, conducted in Nevada, New Mexico, and in the Pacific, were intended to familiarize combat teams with conditions that would be present during a potential war in which atomic weapons might be used. As an example, during the series of five atmospheric tests conducted during operation UPHOT-KNOTHOLE, individual Battalion Combat Teams experienced low-LET γ ray doses as low as 0.4 mSv and as high as 31 mSv. This range of exposures would correspond to the equivalent of about five chest x rays for the lowest exposed combat team to approximately 390 chest x rays for the highest exposed combat team (assuming a dose from one chest x ray to be about 0.08 mSv).

EVIDENCE FOR ADVERSE HEALTH EFFECTS SUCH AS CANCER AND HEREDITARY DISEASE

The mechanisms that lead to adverse health effects after ionizing radiation exposure are not fully understood. Ionizing radiation has sufficient energy to change the structure of molecules, including DNA, within the cells of the human body. Some of those molecular changes are so complex that it may be difficult for the body's repair mechanisms to mend them correctly. However, the evidence is that only a very small fraction of such changes would be expected to result in cancer or other health effects. Radiation-induced mutations would be expected to occur in the reproductive cells of the human body (sperm and eggs) resulting in heritable disease. The latter risk is sufficiently small that it has not been detected in humans, even in thoroughly studied irradiated populations such as Hiroshima and Nagasaki.

As noted above, the most thoroughly studied individuals for the determination of the health effects of ionizing radiation are the survivors of the Hiroshima and Nagasaki atomic bombings. Sixty-five percent of these survivors received a low dose of radiation (less than 100 mSv; the definition of low dose used by BEIR VII report). 100 mSv is equivalent to approximately 40 times the average yearly background radiation exposure worldwide from all sources (2.4 mSv) or roughly 100 times the worldwide background exposure from low-LET radiation, the subject of this report. At dose levels of about 100 to 4000 mSv (about 40 to 1,600 times the average yearly background exposure), excess cancers have been observed in the Japanese atomic-bomb survivors. Excess cancers are numbers of cancers above expected levels of cancer in the population. In the case of *in utero* exposure (exposure of the fetus during pregnancy), excess cancers can be detected at doses as low as 10 mSv¹⁵. At the radiation doses where excess cancers occur in the

¹⁴ National Research Council (2003) A Review of the Dose Reconstruction Program of the Defense Threat Reduction Agency. National Academy Press, Washington, D.C. <http://www.nap.edu/catalog/10697.html>

¹⁵ Doll, R. and R. Wakeford. 1997. Risk of childhood cancer from foetal irradiation. British Journal of

Hiroshima and Nagasaki studies, solid cancers¹⁶ show an increasing rate with increasing dose that is consistent with a linear association. In other words, as the level of exposure to radiation increased, so did the occurrence of solid cancers.

Major advances have occurred during the last decade in several key areas that are relevant to the assessment of risks at low radiation doses. Those advances have contributed to greater insights into the molecular and cellular responses to ionizing radiation and to the nature of the relationship between radiation exposure and the types of damage that underlie adverse health outcomes. Also, more data on radiation-induced cancers in humans have become available since the previous BEIR report on the health effects of low-dose low-LET radiation, and these data are evaluated in this report.

THE BEIR VII RISK MODELS

Estimating Cancer Risk

An important task of the BEIR VII committee was to develop “risk models” for estimating the relationship between exposure to low levels of low-LET ionizing radiation and harmful health effects. The Committee judged that the linear no-threshold model (LNT) provided the most reasonable description of the relation between low dose exposure to ionizing radiation and the incidence of solid cancers that are induced by ionizing radiation. This section of the Public Summary describes the linear no-threshold model, the linear-quadratic model, which the committee adopted for leukemia, and a hypothetical linear model with a threshold. It then gives an example derived from the BEIR VII risk models using a figure with closed circles representing the frequency of cancers in the general population and a star representing estimated cancer incidence from radiation exposure using the BEIR VII risk models. Next, the section explains how the absence of evidence for induced adverse heritable effects in the children of survivors of atomic bombs is consistent with the genetic risk estimated through the use of the doubling dose method in this report.

At doses below 40 times the average yearly background exposure (100 mSv), statistical limitations make it difficult to evaluate cancer risk in humans. A comprehensive review of the biology data led the committee to conclude that the risk would continue in a linear fashion at lower doses without a threshold and that the smallest dose has the potential to cause a small increase in risk to humans. This assumption is termed the “linear-no-threshold” (LNT) model (see figure PS-3).

Radiology 70:130-139.

¹⁶ Solid cancers are cellular growths in organs such as the breast or prostate as contrasted with leukemia, a cancer of the blood and blood forming organs.




FIGURE PS-3. The Committee finds the linear no-threshold (LNT) model to be a computationally convenient starting point. Actual risk estimates improve upon this simplified model by using a dose-and-dose-rate effectiveness factor (DDREF), which is a multiplicative adjustment that results in the downward estimation of risk, and which is roughly equivalent to using the line labeled "Linear No-Threshold (low dose rate). The latter is the zero-dose tangent of the linear quadratic model. While it would be possible to use the linear-quadratic model directly, the DDREF adjustment to the linear model is used to conform with historical precedent dictated in part by simplicity of calculations. In the low dose range of interest there is essentially no difference between the two. This figure is modified from a publication by Brenner and colleagues¹⁷

The BEIR VII committee has developed and presented in Chapter 12 the committee's best risk estimates for exposure to low-dose, low-LET radiation in human subjects. An example of how the data-based risk models developed in this report can be used to evaluate the risk of radiation exposure is illustrated in Figure PS-4. In this example, we calculate the expected cancer risk from a single exposure of 0.1 Sv. This risk depends on both sex and age at exposure with higher risks for females and for those

¹⁷ Brenner, D. J., R. Doll, D. T. Goodhead, E. J. Hall, C. E. Land, J. B. Little, J. H. Lubin, D. L. Preston, R. J. Preston, J. S. Puskin, E. Ron, R. K. Sachs, J. M. Samet, R. B. Setlow, and M. Zaider. 2003. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. *Proc Natl Acad Sci U S A* 100:13761-6.

Prepublication copy Uncorrected Proofs

exposed at younger ages. On average, assuming a sex and age distribution similar to that of the entire US population, the BEIR VII lifetime risk model predicts that approximately one individual in 100 persons would be expected to develop cancer (solid cancer or leukemia) from a dose of 0.1 Sv while approximately 42 of the 100 individuals would be expected to develop solid cancer or leukemia from other causes. Lower doses would produce proportionally lower risks. For example, we predict that approximately one individual in 1000 would develop cancer from an exposure to 0.01 Sv. As another example, approximately one individual in 100 persons would be expected to develop cancer from a lifetime (70 year) exposure to low-LET natural “background” radiation (excludes radon and other high LET radiations). Because of limitations in the data used to develop risk models, risk estimates are uncertain, and estimates that are a factor of two or three larger or smaller cannot be excluded.




FIGURE PS-4. In a lifetime, approximately 42 (solid circles) of 100 people will be diagnosed with cancer¹⁸ from causes unrelated to radiation. The calculations in this report suggest approximately one cancer (star) in 100 people could result from a single exposure to 0.1 Sv of low-LET radiation.

¹⁸ Approximately 42 cancers per 100 individuals calculated from Table 12-4 in chapter 12 of the BEIR VII report.

Health Effects Other Than Cancer

In addition to cancer, radiation exposure has been demonstrated to increase the risk of diseases other than cancer, particularly cardiovascular disease, in persons exposed to high therapeutic doses and also in A-bomb survivors exposed to more modest doses. However, there is no direct evidence of increased risk of non-cancer diseases at low doses, and data are inadequate to quantify this risk if it exists. Radiation exposure has also been shown to increase risks of some benign tumors, but data are inadequate to quantify this risk.

Estimating Risks to Children of Parents Exposed to Ionizing Radiation

Naturally-occurring genetic (that is, hereditary) diseases contribute substantially to illness and death in human populations. Those diseases arise as a result of alterations (mutations) occurring in the genetic material (DNA) contained in the germ cells (sperm and ova) and are heritable (*i.e.*, they can be transmitted to the offspring and subsequent generations). Among the diseases are those that show simple predictable patterns of inheritance (which are rare) such as cystic fibrosis and those with complex patterns (which are common) such as diabetes mellitus. Diseases in the latter group originate from interactions among multiple genetic and environmental factors.

Early in the 20th century, it was demonstrated that ionizing radiation could induce mutations in the germ cells of fruit flies. Those findings were subsequently extended to a number of other organisms including mice, establishing the fact that radiation is a mutagen (an agent that can cause mutations in body cells); human beings are unlikely to be exceptions. Thus began the concern that exposure of human populations to ionizing radiation would cause an increase in the frequencies of genetic diseases. That concern moved to center stage in the aftermath of the detonation of atomic weapons over Hiroshima and Nagasaki in World War II. Extensive research programs to examine the adverse genetic effects of radiation in the children of A-bomb survivors were soon launched. Other studies focusing on mammals that could be bred in the laboratory – primarily the mouse – were also initiated in different research centers around the world.

The aim of the early human genetic studies carried out in Japan was to obtain a *direct* measure of adverse effects in the children of A-bomb survivors. The indicators that were used included: adverse pregnancy outcomes (*i.e.*, stillbirths, early neonatal deaths, and congenital abnormalities); deaths among live-born infants over a follow-up period of about 26 years; growth and development of the children; chromosomal abnormalities; and specific types of mutations. Specific genetic diseases were *not* used as indicators of risk, because not enough was known about them when the studies began.

The *initial* goal of the mouse experiments was to examine the effects of different doses, types, and modes of delivery of radiation on mutation frequencies and the extent to which the germ-cell stages in the two sexes might differ in their responses to radiation-induced mutations. But, as it turned out, the continuing scarcity of data on radiation-induced mutations in humans and the compelling need for quantitative estimates of genetic

risk for formulating adequate measures for radiological protection, necessitated the use of mouse data for indirect prediction of genetic risks in humans.

As in previous BEIR reports, a method, termed the "doubling dose method", is used for predicting the risk of inducible genetic diseases in the children of people exposed to radiation using naturally-occurring genetic diseases as a framework. Doubling dose is defined as the amount of radiation that is required to produce as many mutations as those occurring spontaneously in *one generation*. The doubling dose is expressed as a ratio of *mutation rates*. It is calculated as a ratio of the average spontaneous and induced mutation rates in a set of genes. A large DD indicates small relative mutation risk and a small doubling dose indicates a large relative mutation risk. The DD used in the present report is one Sv (one Gy)¹⁹ and derives from human data on spontaneous mutation rates of disease-causing genes and mouse data on induced mutation rates²⁰. Therefore, if three mutations occur spontaneously in one million people in one generation, six mutations will occur per generation if one million people are each exposed to one Sv of ionizing radiation, and three of these six mutations would be attributed to the radiation exposure.

More than four decades have elapsed since the genetic studies in Japan were initiated. In 1990, the final results of those studies were published. They show (as the earlier reports published from time to time over the intervening years showed) that there are no statistically significant adverse effects detectable in the children of the exposed survivors, indicating that at the relatively low doses sustained by the survivors (of the order of about 400 mSv or less), the genetic risks, as measured by the indicators mentioned earlier, are very small. Other, mostly small-scale studies of the children of those exposed to high doses of radiation for radiotherapy of cancers have also shown no detectable increases in the frequencies of genetic diseases.

During the past 10 years, major advances have occurred in our understanding of the molecular nature and mechanisms underlying naturally-occurring genetic diseases and radiation-induced mutations in experimental organisms including the mouse. Those advances have shed light on the relationships between spontaneous mutations and naturally-occurring genetic diseases and have provided a firmer scientific basis for inferences on the relationships between induced mutations and diseases. The risk estimates presented in this report have incorporated all these advances. They show that, at low or chronic doses of low-LET irradiation, the genetic risks are very small compared to the baseline frequencies of genetic diseases in the population. Additionally, they are consistent with the lack of significant adverse effects in the Japanese studies based on about 30,000 children of exposed survivors. In other words, given the BEIR VII estimates, one would not expect to see an excess in adverse hereditary effects in a sample of about 30,000 children (the number of children evaluated in Hiroshima and Nagasaki). One reason that genetic risks are low is that only those genetic changes compatible with embryonic development and viability will be recovered in live births.

¹⁹ For the purposes of this report, when low-LET radiation is considered, one Gy is equivalent to one Sv.

²⁰ UNSCEAR 2001. Hereditary Effects of Radiation. UNSCEAR 2001 Report to the General Assembly, with Scientific Annex. United Nations, N.Y.

WHAT BODIES OF RESEARCH THE COMMITTEE REVIEWED

The Committee and staff ensured that BEIR VII's conclusions were informed by a thorough review of published, peer-reviewed materials relevant to the Committee's formal Statement of Task. Specifically, the sponsors of this study asked for a comprehensive review of all relevant epidemiologic data (*i.e.*, data from studies of disease in populations) related to health effects of low doses of ionizing radiation. In addition, the Committee was asked to review all relevant biological information important to the understanding or modeling of those health effects. Along with the review of these bodies of literature and drawing upon the accumulated knowledge of the Committee, the Committee members and staff also considered mailings, publications, and emails sent to them. Data on cancer mortality and incidence from the Life Span Study cohort of atomic bomb survivors in Hiroshima and Nagasaki, based on improved dose estimates, were used by the Committee. The Committee also considered radiation-risk information from studies of persons exposed for medical, occupational, and environmental reasons. Models for breast and thyroid cancer drew directly on medical studies. Further information was gathered in open sessions of the committee held at meetings in Washington, DC, and in Irvine, California. Questions and concerns raised in open sessions were considered by Committee members in the writing of this report.

Why has the committee not accepted the view that low doses are substantially more harmful than estimated by the linear no-threshold model?

Some of the materials the Committee reviewed included arguments that low doses of radiation are more harmful than a linear, no-threshold model of effects would suggest. The BEIR VII Committee concluded that radiation health effects research, taken as a whole, does not support this view. In essence, the BEIR VII Committee said that the higher the dose, the greater the risk; the lower the dose, the lower the likelihood of harm to human health. There are several intuitive ways to think about the reasons for this conclusion. First, any single track of ionizing radiation has the potential to cause cellular damage. However, if there is only one ionizing particle passing through a cell's DNA, the chances of damage to that cell's DNA are proportionately lower than if there are 10, 100 or 1000 such ionizing particles passing through it. There is no reason to expect a greater effect at lower doses from the physical interaction of the radiation with the cell's DNA.

New evidence from biology suggests that cells do not necessarily have to be hit directly by a radiation track for the cell to be affected. Some speculate that hit cells communicate with non-hit cells with chemical signals or by other means. To some this suggests that, at very low radiation doses, where all of the cells in the body are not hit, "bystander" cells may be adversely affected, resulting in a greater health effect at low doses than would be predicted by extrapolating the observed response at high doses. Others believe that increased cell death caused by "bystander" effects might lower the risk of cancer by eliminating cells at risk for cancer from the irradiated cell population. While additional research needs to be done on the subject, it is unclear at this time whether the

so-called "bystander" effect would have a net positive or net negative effect on the health of an irradiated person.

In sum, the total body of relevant research for the assessment of radiation health effects provides compelling reasons to believe that the risks associated with low doses of low-LET radiation are no greater than expected on the basis of the linear, no-threshold model.

**Why has the committee not accepted the view that
low doses are substantially less harmful than estimated by the linear no-threshold
model?**

In contrast to the previous section's subject, some materials provided to the Committee suggest that the LNT model exaggerates the health effects of low levels of ionizing radiation. They say that the risks are smaller than predicted by the LNT, are nonexistent, or that low doses of radiation may even be beneficial. The Committee also does not accept this hypothesis. Instead, the Committee concludes that the preponderance of information indicates that there will be some risk, even at low doses. As the simple risk calculations in this Public Summary show, the risk at low doses will be small. Nevertheless, the Committee's principal risk model for solid tumors predicts a linear decrease in cancer incidence with decreasing dose.

Before coming to this conclusion, the BEIR VII Committee reviewed articles arguing that a threshold or decrease in effect does exist at low doses. That is, those reports claimed that at very low doses ionizing radiation does not harm human health or may even be beneficial. Those reports were found either to be based on ecologic studies or to cite findings not representative of the overall body of data.

Ecologic studies assess broad regional associations, and in some cases, such studies have suggested that the incidence of cancer is well above or below numbers seen with more precise epidemiologic studies. When the complete body of research on this question is considered, a consensus view emerges. That view says that health risks of ionizing radiation, while small at low doses, are a function of dose.

Both the epidemiologic data and the biological data are consistent with a linear model at doses where associations can be measured. The main studies establishing the health effects of ionizing radiation are those analyzing survivors of the Hiroshima and Nagasaki atomic bombings in 1945. Sixty-five percent of these survivors received a low dose of radiation; that is, low according to the definition used in this report (equal to or less than 100 mSv). The arguments for thresholds or beneficial health effects are not supported by these data. Other work in epidemiology also supports the view that the harmfulness of ionizing radiation is a function of dose. Further, studies of cancer in children following exposure *in utero* or in early life indicate that radiation-induced cancers can occur at low doses. For example, the Oxford Survey of Childhood Cancer, found a

“40 percent increase in the cancer rate among children up to [age] 15²¹.” This increase was detected at radiation doses in the range of 10 to 20mSv.

There is also compelling support for the linearity view on how cancers form. Studies in radiation biology show that “a single radiation track (resulting in the lowest exposure possible) traversing the nucleus of an appropriate target cell has a low but finite probability of damaging the cell’s DNA.”²² Subsets of this damage, such as ionization “spurs” that can cause multiple damages in a short length of DNA, may be difficult for the cell to repair or may be repaired incorrectly. The Committee concluded that there is no compelling evidence to indicate a dose threshold below which the risk of tumor induction is zero.

CONCLUSIONS

Despite the challenges associated with understanding the health effects of low doses of low LET radiation, current knowledge allows several conclusions. The BEIR VII Committee concludes that the current scientific evidence is consistent with the hypothesis that there is a linear dose-response relationship between exposure to ionizing radiation and the development of radiation-induced solid cancers in humans. The Committee further judges that it is unlikely that a threshold exists for the induction of cancers but notes that the occurrence of radiation-induced cancers at low doses, will be small. The Committee maintains that other health effects (such as heart disease and stroke) occur at high radiation doses but that additional data must be gathered before an assessment of any possible dose response can be made of connections between low doses of radiation and non-cancer health effects. Additionally, the Committee concludes that although adverse health effects in children of exposed parents (attributable to radiation-induced mutations) have not been found, there are extensive data on radiation-induced transmissible mutations in mice and other organisms. There is therefore no reason to believe that humans would be immune to this sort of harm.

²¹ As noted on p. 71 in Cox, R., Muirhead, C. R., Stather, J. W., Edwards, A. A., and Little, M. P. 1995. Risk of radiation-induced cancer at low doses and low dose rates for radiation protection purposes. Documents of the [British] National Radiological Protection Board, Vol. 6, No. 1.

²² As noted on p. 74 Cox, R., Muirhead, C.R., Stather, J.W., Edwards, A.A., and Little, M.P. 1995. Risk of radiation-induced cancer at low doses and low dose rates for radiation protection purposes. Documents of the National Radiological Protection Board, Vol. 6, No. 1.

Executive Summary

INTRODUCTION

This report, prepared by the National Research Council's Committee on the Biological Effects of Ionizing Radiation, is the seventh in a series that addresses the health effects of exposure of human populations to low-dose low-LET (Linear Energy Transfer) ionizing radiation. The current report focuses on new information available since the 1990 BEIR V report on low-dose low-LET health effects.

Ionizing radiation arises from both natural and man-made sources and at very high doses can produce damaging effects in tissues that can be evident within days after exposure. At the low-dose exposures that are the focus of this report, so-called "late" effects, such as cancer, are produced many years after the initial exposure. In this report the committee has defined low doses as those in the range of near 0 up to about 100 milliGray (mGy) of low-LET radiation, with emphasis on the lowest doses for which meaningful effects have been found. Additionally, effects that may occur as a result of chronic exposures over months to a lifetime at dose-rates below 0.1 mGy per minute, irrespective of the total dose, are thought to be most relevant. Medium doses are defined as doses in excess of 100 mGy up to one Gy and high doses encompass doses of one Gy or more, including the very high total doses used in radiotherapy (of the order of 20 to 60 Gy).

Well-demonstrated "late" effects of radiation exposure include the induction of cancer and some degenerative diseases (*e.g.*, cataracts). Also, the induction of mutations in the DNA of germ cells which, when transmitted, have the potential to cause adverse health effects in offspring, have been demonstrated in animal studies.

EVIDENCE FROM BIOLOGY

There is an intimate relationship between DNA damage responses, the appearance of gene/chromosomal mutations, and multi-stage cancer development. Molecular and cytogenetic studies of radiation-associated animal cancers and more limited human data are consistent with the induction of a multistage process of cancer development. This process does not appear to differ from that which applies to spontaneous cancer or cancers associated with exposure to other carcinogens.

Animal data support the view that low-dose radiation acts principally on the early stages of tumorigenesis (initiation). High-dose effects on later stages (promotion/progression) are also likely. Although data are limited, the loss of specific genes whose absence might result in animal tumor initiation has been demonstrated in irradiated animals and cells.

Adaptation, low dose hypersensitivity, bystander effect, hormesis, and genomic instability are mainly based on phenomenological data with little mechanistic information. The data suggest enhancement or reduction in radiation effects and in some cases appear to be restricted to special experimental circumstances.

Radiation-induced cancer: mechanism, quantitative experimental studies, and the role of molecular genetics

A critical conclusion on mechanisms of radiation tumorigenesis is that the data reviewed greatly strengthen the view that there are intimate links between the dose-dependent induction of DNA damage in cells, the appearance of gene/chromosomal mutations through DNA damage misrepair, and the development of cancer. Although less well-established, the data available point towards a single cell (monoclonal) origin for induced tumors. These data also provide some evidence on candidate, radiation-associated mutations in tumors. These mutations include loss-of-function DNA deletions, some of which have been shown to be represented as multigene deletions. Certain point mutations and gene amplifications have also been characterized in radiation-associated tumors, but their origins and status are uncertain.

One mechanistic caveat explored was that novel forms of cellular damage response, collectively termed induced genomic instability, might contribute significantly to radiation cancer risk. The cellular data reviewed in this report identified uncertainties and some inconsistencies in the expression of this multi-faceted phenomenon. However, telomere-associated¹ mechanisms did provide a coherent explanation for some *in vitro* manifestations of induced genomic instability. The data did not reveal consistent evidence for the involvement of induced genomic instability in radiation tumorigenesis, although telomere-associated processes may account for some tumorigenic phenotypes.

Quantitative animal data on dose-response relationships provide a complex picture for low-LET radiation, with some tumor types showing linear or linear-quadratic relationships while studies of other tumor types are suggestive of a low-dose threshold, particularly for thymic lymphoma and ovarian cancer. However, the induction/development of these two cancer types is believed to proceed via atypical mechanisms involving cell killing; therefore it was judged that the threshold-like responses observed should not be generalized. Adaptive responses for radiation tumorigenesis have been investigated in quantitative animal studies, and recent information is suggestive of adaptive processes that increase tumor latency but do not affect life-time risk.

The review of cellular, animal and epidemiologic/clinical studies on the role of genetic factors in radiation tumorigenesis suggest that many of the known strongly expressing cancer-prone human genetic disorders are likely to show an elevated risk of radiation-induced cancer, probably with a high degree of organ specificity. Cellular and animal studies suggests that the molecular mechanisms that underlie these genetically-determined radiation effects largely mirror those that apply to spontaneous tumorigenesis and are consistent with knowledge of somatic mechanisms of tumorigenesis. In particular, evidence was obtained that major deficiencies in DNA damage response and tumor suppressor-type genes can serve to elevate radiation cancer risk

A major theme developing in the study of cancer genetics is the interaction and potential impact of more weakly expressing variant cancer genes that may be relatively common in human populations. Knowledge of such gene-gene and gene-environment interactions, although at an early stage, is developing rapidly. The animal genetic data

¹ Mechanisms associated with the structure and function of telomeres, which are the terminal regions of a chromosome that include characteristic DNA repeats and associated proteins.

provide proof-of-principle evidence on how such variant genes with functional polymorphisms can influence cancer risk, including limited data on radiation tumorigenesis.

Given that functional gene polymorphisms associated with cancer risk may be relatively common, the potential for significant distortion of population-based risk was explored with emphasis on the organ specificity of the genes of interest. A preliminary conclusion is that common polymorphisms of DNA damage response genes associated with organ-wide radiation cancer risk would be the most likely source of major inter-individual differences in radiation response.

ESTIMATION OF HERITABLE GENETIC EFFECTS OF RADIATION IN HUMAN POPULATIONS

In addition to induction of cancers in humans by radiation there is evidence for heritable genetic effects of radiation from animal experiments. It is now possible to estimate risks for all classes of genetic diseases. The advances that deserve particular attention are the following: (a) the introduction of a conceptual change for calculating the doubling dose (from the use of mouse data for *both* spontaneous and induced mutation rates in 1990 to the use of human data on spontaneous mutation rates and mouse data on induced mutation rates now; the latter was the procedure used in the 1972 BEIR report); (b) the elaboration of methods to estimate mutation component (*i.e.*, the relative increase in disease frequency per unit relative increase in mutation rate) and the use of the estimates obtained through these methods for assessing the impact of induced mutations on the incidence of Mendelian and chronic multifactorial diseases; (c) the introduction of an additional factor, called the “potential recoverability correction factor” in the risk equation to bridge the gap between the rates of radiation-induced mutations estimated from mouse data and the predicted risk of radiation-inducible heritable diseases in humans and (d) the introduction of the concept that multi-system developmental abnormalities are likely to be among the principal phenotypes of radiation-induced genetic damage in humans.

The risk estimates presented in this report incorporate all the above advances. They show that, at low or chronic doses of low LET irradiation, the genetic risks are very small compared to the baseline frequencies of genetic diseases in the population.

The total risk for *all* classes of genetic diseases estimated in this report is about 3,000 to 4,700 cases per million first generation progeny per Gy. These figures are about 0.4 to 0.6% of the baseline risk of 738,000 cases per million (of which chronic diseases constitute the predominant component, namely, 650,000 cases per million). The BEIR V risk estimates (which did not include chronic diseases) were < 2400 to 5300 cases per million first generation progeny per Gy. Those figures were about 5 to 14% of the baseline risk of 37,300 to 47,300 cases per million.

EVIDENCE FROM EPIDEMIOLOGY

Atomic bomb survivor studies

The Life Span Study (LSS) cohort of survivors of the atomic bombings in Hiroshima and Nagasaki continues to serve as a major source of information for evaluating health risks from exposure to ionizing radiation and particularly for developing quantitative estimates of risk. The advantages of this population include its large size, slightly less than half of the survivors were alive in 2000, the inclusion of both sexes and all ages, a wide range of doses that have been estimated for individual subjects, and high quality mortality and cancer incidence data. In addition, the whole body exposure received by this cohort offers the opportunity to assess risks for cancers of a large number of specific sites and to evaluate the comparability of site-specific risks. Special studies of subgroups of the LSS have provided clinical data, biological measurements, and information on potential confounders or modifiers.

Mortality data for the period 1950-1997 have been evaluated in detail. Importantly, cancer incidence data from both the Hiroshima and Nagasaki tumor registries became available for the first time in the 1990s. These data not only include non-fatal cancers, but also offer diagnostic information that is of higher quality than that based on death certificates, especially important when evaluating site-specific cancers. The more extensive data on solid cancer that are now available has allowed more detailed evaluation of several issues pertinent to radiation risk assessment. Analyses evaluating the shape of the dose-response and focusing on the large number of survivors with relatively low doses (less than 0.5 Sv) generally confirm the appropriateness of linear functions to describe solid cancer risks. Both excess relative risk and excess absolute risk models have been used to evaluate the modifying effects of sex, age at exposure, and attained age.

Health endpoints other than cancer have been linked with radiation exposure in the LSS cohort. Of particular note, a dose-response relationship with mortality from non-neoplastic disease mortality has been demonstrated with statistically significant associations for the categories of heart disease, stroke, and diseases of the digestive, respiratory and hematopoietic systems. However, non-cancer risks at the low doses of interest for this report are especially uncertain, and the Committee has not modeled the dose-response for non-neoplastic diseases, nor have we developed risk estimates for these diseases.

Medical radiation studies

The published studies on health effects of medical exposures were reviewed to identify those that provide information for quantitative risk estimation. Particular attention was focused on estimating risks of leukemia and of lung, breast, thyroid, and stomach cancer in relation to radiation dose for comparison with the estimates derived from other exposed populations, in particular the atomic bomb survivors.

For lung cancer, the excess relative risk (ERR)² per Gy from the studies of acute or fractionated high dose-rate exposures are statistically compatible and in the range 0.1-0.4 per Gy. For breast cancer, both the ERR and excess absolute risk (EAR)² appear to be quite variable across studies. A pooled analysis of A-bomb survivors and selected medically-exposed cohorts indicated that the EAR for breast cancer was similar (about 10 per 10⁴ person years (PY) per Gy at age 50) following acute and fractionated moderate to high dose-rate exposure despite differences in baseline risks and dose-rate. Women treated for benign breast conditions appeared to be at higher risk while the risk was lower following protracted low dose-rate exposures in hemangioma cohorts.

For thyroid cancer, all of the studies providing quantitative information about risks are studies of children who received radiotherapy for benign conditions. For subjects exposed below the age of 15, a linear dose-response was seen with a leveling or decrease in risk at the higher doses used for cancer therapy (10+ Gy). An ERR of 7.7 per Gy and an EAR of 4.4 per 10⁴ PY per Gy were derived from pooled analyses of data from medical exposures and atomic bomb survivors. Both estimates were significantly affected by age at exposure, with a strong decrease in risk with increasing age at exposure and little apparent risk for exposures after age 20. The ERR appeared to decline over time about 30 years after exposure but was still elevated at 40 years. Little information on thyroid cancer risk in relation to medical ¹³¹I exposure in childhood was available. Studies of the effects of ¹³¹I exposure later in life provide little evidence of an increased risk of thyroid cancer.

For leukemia, ERR estimates from studies with average doses ranging from 0.1 to 2 Gy are relatively close, in the range 1.9 to 5 per Gy, and are statistically compatible. Estimates of EAR are also similar across studies, ranging from 1 to 2.6 per 10⁴ PY per Gy. Little information is available on the effects of age at exposure or of exposure protraction.

For stomach cancer, the estimates of ERR per Gy range from negative to 1.3 per Gy. The confidence intervals are wide, however, and they all overlap, indicating that these estimates are statistically compatible. Finally, studies of patients having undergone radiotherapy for Hodgkin disease (HD) or breast cancer suggest that there may be some risk of cardiovascular morbidity and mortality for very high doses and dose-rate exposures. The magnitude of the radiation risk and the shape of the dose response curve for these outcomes are uncertain.

Occupational radiation studies

Numerous studies have considered the mortality and cancer incidence of various occupationally-exposed groups in medical, manufacturing, nuclear, research, and aviation industries.

The most informative studies are those of nuclear industry workers (including the workers of Mayak in the former USSR), for whom individual real time estimates of doses have been collected over time with the use of personal dosimeters. Over one million workers have been employed in this industry since its beginning in the early 1940s.

² Excess relative risk (ERR) is (the rate of disease in an exposed population divided by the rate of disease in an unexposed population) minus 1.0. Excess absolute risk (EAR) is the (rate of disease in an exposed population minus the rate of disease in an unexposed population.)

Prepublication copy Uncorrected Proofs

Studies of individual worker cohorts are limited, however, in the ability to estimate precisely the potentially small risks associated with low levels of exposure.

Combined analyses of data from multiple cohorts offer an opportunity to increase the sensitivity of such studies and provide direct estimates of the effects of long-term low dose, low-LET radiation. The most comprehensive and precise estimates to date are those derived from the UK National Registry of Radiation Workers (NRRW) and the Three-country study (Canada-UK-USA), which have provided estimates of leukemia and all cancer risks. In these studies, the leukemia risk estimates are intermediate between those derived using linear and linear quadratic extrapolations from the A-bomb survivors' study. The estimate for all cancers is smaller, but the confidence intervals are wide and consistent both with no risk and with risks up to twice the linear extrapolation from the atomic bomb survivors.

Because of remaining uncertainty in the occupational risk estimates and the fact that errors in doses have not been formally taken into account in these studies, the Committee concluded that the risk estimates from occupational studies, although directly relevant to the estimation of effects of low-dose protracted exposures, are not sufficiently precise to form the sole basis for radiation risk estimates.

Environmental studies

Ecologic studies of populations living around nuclear facilities and of other environmentally-exposed populations do not contain individual estimates of radiation dose nor provide a direct quantitative estimate of risk in relation to radiation dose. This limits the interpretation of these data. Several cohort studies have reported health outcomes among persons exposed to environmental radiation. No consistent or generalizable information is contained in these studies.

Results from environmental exposures to ^{131}I have been inconsistent. The most informative findings are from studies of individuals exposed to radiation after the Chernobyl accident. Recent evidence indicates that exposure to radiation from Chernobyl is associated with an increased risk of thyroid cancer, and that the relationship is dose-dependent. The quantitative estimate of excess thyroid cancer risk is generally consistent with estimates from other radiation-exposed populations and is observed in both males and females. Iodine deficiency appears to be an important modifier of risk, enhancing the risk of thyroid cancer following radiation exposure.

INTEGRATION OF BIOLOGY AND EPIDEMIOLOGY

The principal conclusions from this work are:

- Current knowledge on the cellular/molecular mechanisms of radiation tumorigenesis tends to support the application of models that incorporate the excess relative risk projection over time.

Prepublication copy Uncorrected Proofs

- The choice of models for the transport of cancer risk from Japanese A-bomb survivors to the US population is influenced by mechanistic knowledge and information on the etiology of different cancer types.
- A combined Bayesian analysis of A-bomb epidemiologic information and experimental data has been developed to provide an estimation of the dose and dose-rate effectiveness factor (DDREF) for cancer risk estimates reported in this study.
- Knowledge on adaptive responses, genomic instability, and bystander signaling among cells that may act to alter radiation cancer risk was judged to be insufficient to be incorporated in a meaningful way into the modeling of epidemiologic data.
- Genetic variation in the population is a potentially important factor in the estimation of radiation cancer risk. Modeling studies suggest that strongly expressing mutations that predispose humans to cancer are too rare to distort appreciably population-based estimates of risk, but are a significant issue in some medical radiation settings.
- The estimation of the heritable effects of radiation takes advantage of new information on human genetic disease and on mechanisms of radiation-induced germ line mutation. The application of a new approach to genetic risk estimation leads the Committee to conclude that low-dose induced genetic risks are very small when compared to baseline risks in the population.
- The Committee judges that the balance of evidence from epidemiologic, animal and mechanistic studies tend to favor a simple proportionate relationship at low doses between radiation dose and cancer risk. Uncertainties on this judgment are recognized and noted.

Each of the above points contributes to refining earlier risk estimates, but none leads to a major change in the overall evaluation of the relation between exposure to ionizing radiation and human health effects.

ESTIMATING CANCER RISKS

As in past risk assessments, the LSS cohort of survivors of the atomic bombings in Hiroshima and Nagasaki plays a principal role in developing the Committee's recommended cancer risk estimates. Risk models were developed primarily from cancer incidence data for the period 1958-98 and based on DS02 dosimetry, the result of a major international effort to reassess and improve survivor dose estimates. Data from studies involving medical and occupational exposure were also evaluated. Models for estimating risks of breast and thyroid cancer were based on pooled analyses that included both data on both the LSS and medically exposed persons.

Prepublication copy Uncorrected Proofs

To use models developed primarily from the LSS cohort for the estimation of lifetime risks for the US population, it was necessary to make several assumptions that involve uncertainty. Two important sources of uncertainty are 1) the possible reduction in risk for exposure at low doses and dose rates, *i.e.*, the Dose and Dose-Rate Effect Factor (DDREF) and 2) the use of risk estimates based on Japanese atomic bomb survivors for estimating risks for the US population.

The committee has developed and presented in the text the committee’s best possible risk estimates for exposure to low-dose, low-LET radiation in human subjects. As an example, Table ES-1 shows the estimated number of incident cancer cases and deaths that would be expected to result if a population of 100,000 persons with an age distribution similar to that of the entire US population were each exposed to 0.1 Gy, and also shows the numbers that would be expected in the absence of exposure. Results for solid cancers are based on linear models and reduced by a DDREF of 1.5. Results for leukemia are based on a linear-quadratic model.

The estimates are accompanied by 95% subjective confidence intervals (*i.e.* random as well as judgmental) that reflect the most important uncertainty sources, namely, statistical variation, uncertainty in the factor used to adjust risk estimates for exposure at low doses and dose rates, and uncertainty in the method of transport. The committee also presents in the text of the report example estimates for each of several specific cancer sites and other exposure scenarios, although they are not shown here.

TABLE ES-1 The Committee’s preferred estimates of the lifetime attributable risk (LAR) of incidence and mortality for all solid cancers and for leukemia with 95% subjective confidence intervals. Number of cases or deaths per 100,000 exposed persons.

	All solid cancer		Leukemia	
	Males	Females	Males	Females
Excess cases (including non-fatal cases) from exposure to 0.1 Gy	800 (400, 1600)	1300 (690, 2500)	100 (30, 300)	70 (20, 250)
Number of cases in the absence of exposure	45,500	36,900	830	590
Excess deaths from exposure to 0.1 Gy	410 (200, 830)	610 (300, 1200)	70 (20, 220)	50 (10, 190)
Number of deaths in the absence of exposure	22,100	17,500	710	530

In general the magnitude of estimated risks for total cancer mortality or leukemia has not changed greatly from estimates provided in past reports such as BEIR V and recent UNSCEAR and ICRP reports. New data and analyses have reduced sampling uncertainty, but uncertainties related to estimating risk for exposure at low doses and dose rates and to transporting risks from Japanese A-bomb survivors to the U.S. population remain large. Uncertainties in estimating risks of site-specific cancers are especially large.

As an illustration, Figure ES-1 shows estimated excess relative risks (ERR) of solid cancer versus dose (averaged over sex, and standardized to represent individuals exposed at age 30 and at attained age 60), for atomic bomb survivors with doses in each of 11 dose intervals less than 2.0 Sv. The figure in the insert represents ERR vs. dose for leukemia. This plot conveys the overall dose-response relationship from the LSS cohort and its role

in low-dose risk estimation. It is important to note that the difference between the linear and linear-quadratic models in the low-dose ranges is small relative to the error bars; therefore, the difference between these models is small relative to the uncertainty in the risk estimates produced from them. For solid cancer incidence the linear-quadratic model did not offer statistically significant improvement in the fit, so the linear model was used. For leukemia, a linear-quadratic model (insert figure ES-1) was used since it fitted the data significantly better than the linear model.




FIGURE ES-1. Excess Relative Risks of Solid Cancer for the Japanese Atomic Bomb Survivors. The plotted points are the estimated excess relative risks of solid cancer incidence (averaged over sex, and standardized to represent individuals exposed at age 30 and at attained age 60) for atomic bomb survivors with doses in each of 10 dose intervals, plotted above the midpoints of the dose intervals. If $R(d)$ represents the age-specific instantaneous risk at some dose d , then the *excess relative risk* at dose d is $[R(d) - R(0)]/R(0)$ (which is necessarily zero when dose is zero). The vertical lines are approximate 95% confidence intervals. The solid and dotted lines are estimated linear and

linear-quadratic models for excess relative risk, estimated from all subjects with doses in the range 0 to 1.5 Sv. (These are not estimated from the points; but from the lifetimes and doses of the individual survivors, using statistical methods discussed in Chapter 6). A linear-quadratic model will always fit the data better than a linear model, since the linear model is a restricted special case with quadratic coefficient equal to zero. For solid cancer incidence, however, there is no *statistically significant* improvement in fit due to the quadratic term. It should also be noted that in the low dose range of interest the difference between the estimated linear and linear-quadratic models is small relative to the 95% confidence intervals. The insert shows the fit of a linear-quadratic model for leukemia, to illustrate the greater degree of curvature observed for that cancer.

CONCLUSION

The Committee concludes that the current scientific evidence is consistent with the hypothesis that there is a linear, no-threshold dose-response relationship between exposure to ionizing radiation and the development of cancer in humans.

BEIR VII RECOMMENDED RESEARCH NEEDS

A more detailed listing of the BEIR VII recommended research needs is found at the end of Chapter 13.

Research Need 1. Determination of the level of various molecular markers of DNA damage as a function of low dose ionizing radiation.

Currently identified molecular markers of DNA damage and other biomarkers that can be identified in the future should be used to quantify low levels of DNA damage and to identify the chemical nature and repair characteristics of the damage to the DNA molecule.

Research Need 2. Determination of DNA repair fidelity, especially as regards double and multiple strand breaks at low doses, and whether repair capacity is independent of dose.

Repair capacity at low levels of damage needs to be investigated, especially in light of conflicting evidence for stimulation of repair at low doses. In these studies the accuracy of DNA sequences rejoined by these pathways needs to be determined, and the mechanisms of error-prone repair of radiation lesions need to be elucidated.

Research Need 3. Evaluation of the relevance of adaptation, low-dose hypersensitivity, bystander effect, hormesis, and genomic instability for radiation carcinogenesis.

Mechanistic data are needed to establish the relevance of these processes to low dose radiation exposure, *i.e.* <100 mGy. Relevant end points should include not only chromosomal aberrations and mutations but also genomic instability and induction of cancer. *In vitro* and *in vivo* data are needed for delivery of low doses over several weeks or months at very low dose rates or with fractionated exposures. The cumulative effect of multiple low doses of less than 10 mGy delivered over extended periods needs to be

explored further. The development of *in vitro* transformation assays utilizing non-transformed human diploid cells is judged to be of special importance.

Research Need 4. Identification of molecular mechanisms for postulated hormetic effects at low doses.

Definitive experiments that identify molecular mechanisms are needed to establish whether hormetic effects exist for radiation-induced carcinogenesis.

Research Need 5. Tumorigenic Mechanisms

Further cytogenetic and molecular genetic studies are needed to reduce current uncertainties on the specific role of radiation in multi-stage radiation tumorigenesis.

Research Need 6. Genetic factors in radiation cancer risk.

Further work is needed in humans and mice on gene mutations and functional polymorphisms that influence radiation response and cancer risk.

Research need 7. Heritable genetic effects of radiation

Further work is needed to establish (a) the potential roles of DNA double strand break (DSB) repair processes in the origin of deletions in irradiated stem cell spermatogonia and oocytes (the germ cell stages of importance in risk estimation) in mice and humans and (b) the extent to which large radiation-induced deletions in mice are associated with multi-system development defects. In humans, the problem can be explored using genomic databases and knowledge of mechanisms of origin of radiation-induced deletions to predict regions that may be particularly prone to radiation-inducible deletions.

With respect to epidemiology, studies on genetic effects of radiotherapy for childhood cancer, should be encouraged, especially when they can be coupled with modern molecular techniques (such as array-based comparative genomic hybridization).

Research Need 8. Future medical radiation studies.

Most studies of medical radiation should rely on exposure information collected prospectively, including cohort studies as well as nested case-control studies. Future studies should continue to include individual dose estimation to the site of interest, as well as an evaluation of the uncertainty in the dose estimation.

Studies of populations with high and moderate dose medical exposures are particularly important for the study of modifiers of radiation risks. Because of the high level of radiation exposure in these populations, they are also ideally suited to study the effects of gene-radiation interactions, which may render particular subsets of the population more sensitive to radiation-induced cancer. Genes of particular interest include BRCA1, BRCA2, ATM, CHEK2, NBS1, XRCC1, and XRCC3.

Of concern for radiological protection is the increasing use of computed tomography (CT) scans and diagnostic X rays. Epidemiologic studies of the following exposed populations, if feasible, would be particularly useful: (1) Follow-up studies of persons receiving CT scans, especially children; (2) Studies of infants who experience

diagnostic exposures related to cardiac catheterization, those who have recurrent exposures to follow their clinical status, and premature babies monitored for pulmonary development with repeated X rays.

There is a need to organize worldwide consortia that would use similar methods in data collection and follow-up. These consortia should record delivered doses and technical data from all x ray or isotope-based imaging approaches including CT, positron emission tomography (PET), and Single Photon Emission Computed Tomography (SPECT).

Research Need 9. Future occupational radiation studies.

Studies of occupational radiation exposures, in particular among nuclear industry workers, including nuclear power plant workers, are well suited for the direct assessment of the carcinogenic effects of long-term, low-level radiation exposure in humans. Ideally, studies of occupational radiation should be prospective in nature, and rely on individual real time estimates of radiation doses. Where possible, national registries of radiation exposure to workers should be established and updated as additional radiation exposure is accumulated and as workers change employers. These registries should include at least annual estimates of whole-body radiation dose from external photon exposure. These exposure registries should be linked with mortality registries and, where they exist, national tumor (and other disease) registries. It is also important to continue follow-up of workers exposed to relatively high doses, that is, workers at the Mayak nuclear facility and workers involved in Chernobyl clean-up.

Research Need 10. Future environmental radiation studies.

In general, additional ecologic studies of persons exposed to low levels of radiation from environmental sources are not recommended. However, if there are disasters where a local population is exposed to unusually high levels of radiation, it is important that there be a rapid response not only for prevention of further exposure but also for establishment of scientific evaluation of the possible effects of the exposure. The data collected should include basic demographic information on individuals, estimates of acute and possible continuing exposure, the nature of the ionizing radiation, and the means of following these individuals for many years. The possibility of enrolling a comparable non-exposure population should be considered. Studies of persons exposed environmentally as a result of the Chernobyl disaster or as a result of releases from the Mayak nuclear facility should continue.

Research Need 11. Japanese Atomic-bomb survivor studies.

The Life Span Study cohort of Japanese A-bomb survivors has played a central role in BEIR VII and in past risk assessments. It is important that follow-up for mortality and cancer incidence continue for the 45% of the cohort who remained alive at the end of 2000.

In the near future, an uncertainty evaluation of the DS02 dosimetry system is expected to become available. Dose-response analyses that make use of this evaluation should thus be conducted to account for dosimetry uncertainties.

Prepublication copy Uncorrected Proofs

Development and application of analytic methods that allow more reliable estimation of site-specific estimates is also needed. Specifically, methods that draw on both data for the specific site and data on broader cancer categories could be useful.

Research Need 12. Epidemiologic studies in general

Data from the Life Span Study cohort of A-bomb survivors should be supplemented with data on populations exposed to low doses and/or dose rates, especially those with large enough doses to allow risks to be estimated with reasonable precision. Studies of nuclear industry workers and careful studies of persons exposed in countries of the former Soviet Union are particularly important in this regard.

**PREPUBLICATION COPY
UNCORRECTED PROOFS**

**Health Risks From Exposure to
Low Levels of Ionizing Radiation**

BEIR VII–Phase 2

Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation

Board on Radiation Effects Research
Division on Earth and Life Studies

NATIONAL RESEARCH COUNCIL
OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS
Washington, D.C.
www.nap.edu

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.

This study was supported by EPA Grant #X-826842-01 and NRC Grant # NRC-04-98-061. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the organizations or agencies that provided support for the project.

International Standard Book Number	(Book)
International Standard Book Number	(PDF)
Library of Congress Control Number	

Additional copies of this report are available from the National Academies Press, 500 Fifth Street, N.W., Lockbox 285, Washington, DC 20055; (800) 624-6242 or (202) 334-3313 (in the Washington metropolitan area); Internet, <http://www.nap.edu>.

Copyright 2005 by the National Academy of Sciences. All rights reserved.

Printed in the United States of America.

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

The **National Academy of Sciences** is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences.

The **National Academy of Engineering** was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. Wm. A. Wulf is president of the National Academy of Engineering.

The **Institute of Medicine** was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine.

The **National Research Council** was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy's purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Ralph J. Cicerone and Dr. Wm. A. Wulf are chair and vice chair, respectively, of the National Research Council.

www.national-academies.org

COMMITTEE TO ASSESS HEALTH RISKS FROM EXPOSURE TO LOW LEVELS OF IONIZING RADIATION

RICHARD R. MONSON (*Chairman*), Harvard School of Public Health,
Boston, MA
JAMES E. CLEAVER, (*Vice Chairman*), University of California, San Francisco, CA
HERBERT L. ABRAMS, Stanford University, Stanford, CA
EULA BINGHAM, University of Cincinnati, Cincinnati, OH
PATRICIA A. BUFFLER, University of California, Berkeley, CA
ELISABETH CARDIS, International Agency for Research on Cancer, Lyon, France
ROGER COX, National Radiological Protection Board, United Kingdom
SCOTT DAVIS, University of Washington and Fred Hutchinson Cancer Research
Center, Seattle, WA
WILLIAM C. DEWEY, University of California, San Francisco, San Francisco,
CA
ETHEL S. GILBERT, National Cancer Institute, Rockville, MD
ALBRECHT M. KELLERER, Ludwig-Maximilians-Universität, München, Germany
DANIEL KREWSKI, University of Ottawa, Ottawa, Ontario, Canada
TOMAS R. LINDAHL, Cancer Research UK London Research Institute, United
Kingdom
KATHERINE E. ROWAN, George Mason University, Fairfax, VA
K. SANKARANARAYANAN, Leiden University Medical Centre, Leiden, The
Netherlands
DANIEL W. SCHAFER, Oregon State University, Corvallis, OR (from May 2002)
LEONARD A. STEFANSKI, North Carolina State University, Raleigh, NC (through
May 2002)
ROBERT L. ULLRICH, Colorado State University, Fort Collins, CO

CONSULTANTS

JOHN D. BOICE, Jr., International Epidemiology Institute, Rockville, MD
KIYOHICO MABUCHI, National Cancer Institute, Rockville, MD

NATIONAL RESEARCH COUNCIL STAFF

RICK JOSTES, Study Director
EVAN B. DOUPLE, BRER Director
DONALD A. PIERCE, Research Advisor RERF
COURTNEY GIBBS, Program Assistant
DORIS E. TAYLOR, Staff Assistant
CATHIE BERKLEY, Financial Officer
NATIONAL ACADEMY PRESS, Editor

BOARD ON RADIATION EFFECTS RESEARCH

S. JAMES ADELSTEIN (*Chairman*), Harvard Medical School, Boston, MA
HAROLD L. BECK, Department of Energy Environmental Laboratory (Retired), New York, NY
JOEL S. BEDFORD, Colorado State University, Fort Collins, CO
JAMES E. CLEAVER, University of California San Francisco Cancer Center, San Francisco, CA
SARAH S. DARBY, University of Oxford, United Kingdom
SHARON L. DUNWOODY, University of Wisconsin, Madison, WI
C. CLIFTON LING, Memorial Sloan-Kettering Cancer Center, New York, NY
DANIEL KREWSKI, University of Ottawa, Ottawa, Canada
THEODORE L. PHILLIPS, University of California, San Francisco, CA
ANDREW M. SESSLER, E.O. Lawrence Berkeley National Laboratory, Berkeley, CA
National Laboratory, Berkeley, CA
JOHN C. VILLFORTH, Food and Drug Law Institute (Retired), Derwood, MD
PAUL L. ZEIMER, Purdue University, West Lafayette, IN

NATIONAL RESEARCH COUNCIL STAFF

EVAN B. DOUPLE, Director, Board on Radiation Effects Research
ISAF AL-NABULSI, Senior Program Officer
RICK JOSTES, Senior Program Officer
CATHERINE S. BERKLEY, Administrative Associate
COURTNEY GIBBS, Program Assistant
DORIS TAYLOR, Staff Assistant

Preface

BACKGROUND

This is the seventh in a series of reports from the National Research Council prepared to advise the U.S. government on the relationship between exposure to ionizing radiation and human health. In 1996 the National Academies (NAS) was requested by the U.S. Environmental Protection Agency to initiate a scoping study preparatory to a new review of the health risks from exposure to low levels of ionizing radiations. The main purpose of the new review would be to update the Biological Effects of Ionizing Radiation V (BEIR V) report (NRC 1990), using new information from epidemiologic and experimental research that has accumulated during the 10 years since the 1990 review. Analysis of those data would help to determine how regulatory bodies should best characterize risks at the doses and dose rates experienced by radiation workers and members of the general public. BEIR VII-phase 1 was the preliminary survey to evaluate whether it was appropriate and feasible to conduct a BEIR VII-phase 2 study. The phase 1 study determined that it was appropriate and feasible to proceed to a phase 2 study. The phase 1 study, *Health Effects of Exposure to Low Levels of Ionizing Radiations: Time for Reassessment?*, published in 1998, also provided the basis for the phase 2 Statement of Task that follows:

BEIR VII PHASE 2 STATEMENT OF TASK

The primary objective of the study is to develop the best possible risk estimate for exposure to low-dose, low-linear energy transfer (LET) radiation in human subjects. In order to do this, the committee will 1) conduct a comprehensive review of all relevant epidemiologic data related to the risk from exposure to low-dose, low-LET radiation; 2) define and establish principles on which quantitative analyses of low-dose and low dose-rate effects can be based, including requirements for epidemiologic data and cohort characteristics; 3) consider relevant biologic factors (such as the dose- and dose-rate effectiveness factor, relative biologic effectiveness, genomic instability, and adaptive responses) and appropriate methods to develop etiologic models (favoring simple as opposed to complex models) and estimate population detriment; 4) assess the current status and relevance to risk models of biologic data and models of carcinogenesis, including critical assessment of all data that might affect the shape of the response curve at low doses, in particular, evidence for or against thresholds in dose-response relationships and evidence for or against adaptive responses and radiation hormesis; 5) consider when appropriate potential target cells and problems that might exist in determining dose to the target cell; and 6) consider any recent evidence regarding genetic effects not related to cancer. In performing the above tasks, the committee should consider all relevant data, even if obtained from high radiation exposures or at high dose rates.

With respect to modeling, the committee will 1) develop appropriate risk models for all cancer sites and other outcomes for which there is adequate data to support a quantitative estimate of risk, including benign disease and genetic effects; 2) provide examples of specific risk calculations based on the models and explain the appropriate use of the risk models; 3) describe and define the limitations and uncertainties of the risk

models and their results; 4) discuss the role and effect of modifying factors, including host (such as individual susceptibility and variability, age, and sex), environment (such as altitude and UV), and lifestyle (such as smoking history and alcohol consumption) factors; and 5) identify critical gaps in knowledge that should be filled by future research.

WHAT HAS CHANGED SINCE THE LAST BEIR REPORT ON THE HEALTH EFFECTS OF LOW LEVELS OF LOW-LET IONIZING RADIATION

In the 15 years since the publication of the previous BEIR report on Low LET radiation (BEIR V) much new information has become available on the health effects of ionizing radiation. Since the 1990 BEIR V report, substantial new information on radiation-induced cancer has become available from the Hiroshima and Nagasaki survivors, slightly less than half of whom were alive in 2000. Of special importance is the cancer incidence data from the Hiroshima and Nagasaki tumor registries. The committee evaluated nearly 13,000 incidence cancers and approximately 10,000 cancer deaths in contrast to fewer than 6000 cancer deaths available to the BEIR V committee. Also, since completion of the 1990 report, additional evidence has emerged from studies of the Hiroshima and Nagasaki bomb survivors suggesting that other health effects, such as cardiovascular disease and stroke, can result from radiation exposure.

A major reevaluation of the dosimetry at Hiroshima and Nagasaki has recently been completed that lends more certainty to dose estimates and provides increased confidence in the relationship between radiation exposure and health effects observed in the Japanese A-bomb survivors. Additional new information is also available from radiation-worker studies, medical-radiation exposures, and populations with environmental exposures.

Although the cancer risk estimates have not changed greatly since the 1990 report, confidence in the estimates has risen because of the increase in epidemiologic and biological data available to the committee.

Progress has also been made since the 1990 report in areas of science that relate to the estimation of genetic (hereditary) effects of radiation. In particular (a) advances in human molecular biology have been incorporated into the conceptual framework of genetic risk estimation and (b) it has become possible to project risks for all classes of genetic diseases, i.e., those with **more** complex as well as simple patterns of inheritance.

Advances in cell and molecular biology have also contributed new information on the mechanisms through which cells respond to radiation-induced damage and to the close associations between DNA damage response and cancer development.

ORGANIZATION OF THE STUDY

The National Research Council appointed a committee comprised of scientists and educators. Some had particular expertise in conducting research on ionizing radiation, while others were experienced in fields relevant to the Committee's charge. The NRC vetted all potential members to assure that each was free from any apparent or potential conflict of interest. The work of the committee was conducted with the assistance of the Board of Radiation Effects Research (BRER) of the Division on Earth and Life Sciences.

The Committee held 11 meetings over a period of 4.5 years. The long time duration of the Committee was largely due to a period of reduced activity while awaiting completion of the update of the dosimetry and exposure estimates to atomic bomb survivors of Hiroshima and Nagasaki, Japan (the so-called DS-02: Dosimetry System, 2002).

Six of the meetings included participation from the public for a portion of the meeting, and five of the meetings were conducted exclusively in executive session. Each meeting included extensive deliberations involving the Committee as a whole; in addition, two major subcommittees were formed that were termed “biology” and “epidemiology”. Dr. Monson convened the epidemiology sessions and Dr. Cleaver convened the biology sessions. Also, a number of loosely organized and non-permanent working groups were formed to discuss the many issues before the Committee. This enabled biologists and non-biologists to work together and to evaluate each other’s work.

ORGANIZATION OF THE REPORT

As noted under our STATEMENT OF TASK, our focus was to develop the best possible risk estimate for exposure to low-dose, low-LET radiation in human subjects. Accordingly, chapters 1-4 discuss basic aspects of radiation physics and radiation biology, including the known interaction between radiation exposure and genetic material, cellular structures, and whole organisms. Chapters 5-9 discuss basic principles of epidemiology as well as substantive data relating to exposure from the atomic bombs, medical radiation, occupational radiation, and environmental radiation. Chapters 10-12, to the extent possible, integrate the information from biology and epidemiology and develop risk estimates based on this information. Three summary sections provide different levels of description of the report. Chapter 13 is an overall scientific summary and lays out the Research Needs that the Committee has identified. The Executive Summary is an abbreviated and reorganized version of Chapter 13 that provides an overview of the report. The Public Summary addresses the findings of the Committee as well as how the report is relevant to public concerns about exposure to ionizing radiation.

REVIEWERS

This report has been reviewed in draft form by persons chosen for their diverse perspectives and technical expertise in accordance with procedures approved by the National Research Council's Report Review Committee. The purposes of this review are to provide candid and critical comments that will assist the institution in making the published report as sound as possible and to ensure that the report meets institutional standards of objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the deliberative process. We wish to thank the following for their participation in the review of this report:

Seymour Abrahamson, University of Wisconsin, Madison, WI
John F. Ahearne, Sigma Xi, The Scientific Research Society, Research Triangle Park, NC
Allan Balmain, University of California, San Francisco, CA
Michael Cornforth, University of Texas, Galveston, TX
James F. Crow, University of Wisconsin, Madison, WI
Richard D. Hichwa, University of Iowa, Iowa City, IA
John Easton, University of Chicago Hospitals, Chicago, IL
Eric J. Hall, Columbia University College of Physicians and Surgeons, New York, NY
Hedvig Hricak, Memorial Sloan-Kettering Cancer Center, New York, NY
Glenn F. Knoll, University of Michigan, Ann Arbor, MI
Jack S. Mandel, Emory University Rollins School of Public Health, Atlanta, GA
John P. Murnane, University of California, San Francisco, CA
Hooshang Nikjoo, National Aeronautics and Space Administration, Houston, TX
Jonathan M. Samet, Johns Hopkins University, Baltimore, MD
Susan S. Wallace, University of Vermont, Burlington, VT
Chris G. Whipple, ENVIRON International Corporation, Emeryville, CA

Although the reviewers listed above have provided many constructive comments and suggestions, they were not asked to endorse the conclusions or recommendations, nor did they see the final draft of the report before its release. The review of this report was overseen by George M. Hornberger, Ernest H. Ern Professor of Environmental Sciences & Associate Dean for the Sciences, University of Virginia, and John C. Bailer, III, Professor Emeritus, University of Chicago. Appointed by the National Research Council, they were responsible for making certain that an independent examination of this report was carried out in accordance with institutional procedures and that all review comments were carefully considered. Responsibility for the final content of this report rests entirely with the author committee and the National Research Council.

GENERAL ACKNOWLEDGEMENTS

The Committee thanks the Directors and Staff of the Radiation Effects Research Foundation, Hiroshima, Japan for providing the most current Life Span Study data on the Japanese atomic-bomb survivors. These data continue to be the primary source of epidemiologic information on the relationship between exposure to ionizing radiation and

its effects on human health. In particular, Dr. Donald Pierce was especially helpful in communication between RERF and the Committee; also, he added his insightful experience to the work of the Committee.

The Committee was aided in its consideration of its charge not only by comments from the public but also by formal presentations by experts from a number of fields. The following presentations were made as part of the public portion of the meetings (in order of appearance):

Presentations by Sponsors

Jerome Puskin, Ph.D.
Environmental Protection Agency

Vincent Holahan, Ph.D.
US Nuclear Regulatory Commission

Bonnie Richter, Ph.D.
US Department of Energy

Scientific speakers

John Boice, Ph.D.
International Epidemiology Institute
Epidemiology that should be considered by BEIR VII.

Charles Waldren, Ph.D.
Colorado State University
Adaptive effects, genomic instability, and bystander effects.

John Ward, Ph.D.
University of California San Diego
Differences between ionizing-radiation-induced DNA damage and endogenous oxidative damage.

Antone Brooks, Ph.D.
Washington State University Tri-cities
Overview of projects funded by the DOE low-dose program.

Charles Land, Ph.D.
National Institute of Health
NCI's update of the 1985 NIH Radioepidemiologic Tables.

L.B. Russell, Ph.D.
Oak Ridge National Laboratory
Early information derived from radiation-induced mutations in mice.

R. Chakraborty, Ph.D.
University of Texas School of Public Health
Mini- and microsatellite mutations and their possible relevance for genetic risk estimation.

Allan Balmain, Ph.D.
University of California, San Francisco
High and low penetrance genes involved in cancer incidence.

Al Fornace, Ph.D.
Harvard School of Public Health
Functional genomics and informatics approaches to categorize radiation response.

Steve Wing, Ph.D.
University of North Carolina
The relevance of occupational epidemiology to radiation risk assessment.

Edward Calabrese, Ph.D.
University of Massachusetts
Radiation hormesis.

David Utterback, Ph.D.
National Institute of Occupational Safety & Health
Exposure Assessment and Radiation Worker Studies.

Sharon Dunwoody, Ph.D.
University of Wisconsin
Challenges in the Communication of Scientific Uncertainties.

Suresh Moolgavkar, Ph.D., M.B.B.S.
School of Public Health and Community Medicine at the University of Washington and the Fred Hutchinson Cancer Research Center
Biology-based models.

We thank these presenters and all other members of the public who spoke on issues related to ionizing radiation.

We thank Doris Taylor and Cathie Berkley for their administrative assistance in assuring that the members of the Committee showed up at the right place at the right time. We also were aided in the work of the Committee by a talented group of Program Assistants. We thank Courtney Gibbs for her assistance in the preparation of this manuscript. We thank Courtney Slack, a Christine Mirzayan Science and Technology Policy Graduate Fellow who provided additional valuable assistance to NRC staff.

We thank Dr. Evan Douple for pulling us in and for holding us together. His wise and patient counsel along with his gentle encouragement, when needed, kept the Committee focused on its charge.

Finally, special thanks are due to Dr. Rick Jostes, the Study Director. His scientific expertise, persistence, equanimity, and organizational skills were essential to our staying the course.

RICHARD MONSON, *chairman*

CONTENTS

UNITS USED TO EXPRESS RADIATION DOSE	1
PUBLIC SUMMARY.....	3
INTRODUCTION	3
HOW IONIZING RADIATION WAS DISCOVERED	4
HOW IONIZING RADIATION IS DETECTED.....	5
UNITS USED TO DESCRIBE RADIATION DOSE	5
WHAT WE MEAN BY LOW DOSES OF IONIZING RADIATION.....	6
EXPOSURE FROM NATURAL "BACKGROUND" RADIATION	6
CONTRIBUTION OF MAN-MADE RADIATION TO PUBLIC EXPOSURE	8
SCENARIOS ILLUSTRATING HOW PEOPLE MIGHT BE EXPOSED TO IONIZING RADIATION ABOVE BACKGROUND LEVELS.....	10
<i>Whole Body Scans</i>	10
<i>Working Near Ionizing Radiation</i>	11
<i>Veterans Exposed to Radiation through Weapons Testing</i>	11
EVIDENCE FOR ADVERSE HEALTH EFFECTS SUCH AS CANCER AND	12
HEREDITARY DISEASE	12
THE BEIR VII RISK MODELS	13
<i>Estimating Cancer Risk</i>	13
<i>Health Effects Other Than Cancer</i>	16
<i>Estimating Risks to Children of Parents Exposed to Ionizing Radiation</i>	16
WHAT BODIES OF RESEARCH THE COMMITTEE REVIEWED	18
<i>Why has the committee not accepted the view that</i>	18
<i>low doses are substantially more harmful than estimated by the linear no-threshold model?</i>	18
<i>Why has the committee not accepted the view that</i>	19
<i>low doses are substantially less harmful than estimated by the linear no-threshold model?</i>	19
CONCLUSIONS	20
EXECUTIVE SUMMARY	21
INTRODUCTION	21
EVIDENCE FROM BIOLOGY	21
ESTIMATION OF HERITABLE GENETIC EFFECTS OF RADIATION IN HUMAN POPULATIONS	23
EVIDENCE FROM EPIDEMIOLOGY	24
<i>Atomic bomb survivor studies</i>	24
<i>Medical radiation studies</i>	24
<i>Occupational radiation studies</i>	25
<i>Environmental studies</i>	26
INTEGRATION OF BIOLOGY AND EPIDEMIOLOGY	26
<i>The principal conclusions from this work are:</i>	26
ESTIMATING CANCER RISKS.....	27
CONCLUSION	30
BEIR VII RECOMMENDED RESEARCH NEEDS	30
1 BACKGROUND INFORMATION	34
PHYSICAL ASPECTS OF RADIATION	34
<i>Different Types of Ionizing Radiation</i>	34
<i>Photon Spectral Distributions</i>	36
<i>Different Effectiveness of γ rays and x rays</i>	39
<i>Radiation type</i>	41
<i>Relative Biological Effectiveness of Neutrons</i>	47
CHEMICAL ASPECTS OF RADIATION	49

<i>Electron Ionization of Water Molecules and Indirect Effects on DNA</i>	49
<i>Spontaneous DNA Damage Relative to Radiation-Induced DNA Damage</i>	51
<i>Background Radiation</i>	52
<i>Locally Multiply Damaged Sites</i>	53
MOLECULAR MECHANISMS OF DNA REPAIR.....	54
<i>Base-Excision Repair</i>	55
<i>Nucleotide-Excision Repair of Cyclodeoxynucleosides</i>	58
<i>Nonhomologous end joining – fast reaction</i>	60
<i>Nonhomologous end joining – slow reaction</i>	63
<i>Homologous Recombination</i>	63
<i>Double-Strand-Break Signal Transduction and Inducible Repair</i>	65
SUMMARY.....	67
ANNEX 1-A IONIZING RADIATION AND OXIDATIVE DAMAGE – A VIEWPOINT FROM <i>SACCHAROMYCES CEREVISIAE</i>	69
2 MOLECULAR AND CELLULAR RESPONSES TO IONIZING RADIATION	73
GENERAL ASPECTS OF DOSE-RESPONSE RELATIONSHIPS.....	73
INDUCTION OF CHROMOSOME ABERRATIONS.....	75
INDUCTION OF GENE MUTATIONS IN SOMATIC CELLS.....	78
RADIATION-INDUCED GENOMIC INSTABILITY.....	80
CELL CYCLE EFFECTS.....	83
ADAPTIVE RESPONSE.....	85
BYSTANDER EFFECTS.....	90
HYPER RADIATION SENSITIVITY AT LOW DOSES.....	93
OBSERVED DOSE-RESPONSE RELATIONSHIPS AT LOW DOSES.....	97
SUMMARY OF CHAPTER 2.....	106
3 RADIATION-INDUCED CANCER: MECHANISMS, QUANTITATIVE EXPERIMENTAL STUDIES AND THE ROLE OF GENETIC FACTORS	110
INTRODUCTION.....	110
MECHANISMS OF TUMORIGENESIS.....	111
<i>Gene and chromosomal mutations in spontaneously arising human tumors</i>	111
<i>Mechanisms of radiation tumorigenesis</i>	114
<i>Gene and chromosomal mutations in radiation-associated human tumors</i>	114
<i>Gene and chromosomal mutations in animal tumors</i>	115
RADIATION-INDUCED GENOMIC INSTABILITY IN RADIATION TUMORIGENESIS.....	119
<i>Chromatid instability in hematopoietic cells</i>	119
<i>Chromatid instability in mouse mammary epithelial cells</i>	120
QUANTITATIVE STUDIES IN EXPERIMENTAL TUMORIGENESIS.....	123
<i>General aspects of dose-response</i>	123
<i>Specific Murine Neoplasms</i>	124
<i>Fractionation kinetics</i>	128
<i>Post-irradiation persistence of initiated cells</i>	129
<i>Radiation-induced life shortening</i>	129
<i>Determining Dose and Dose Rate Effectiveness Factors from Animal Studies</i>	131
GENETIC SUSCEPTIBILITY TO RADIATION-INDUCED CANCER.....	133
<i>Cancer-prone Human Genetic Disorders</i>	134
<i>Mechanistic Aspects of Genetically Determined Radiation Response</i>	139
<i>Cellular Data on Heritable Human Radiosensitivity</i>	141
<i>Animal Data on Radiosensitivity and Tumorigenesis</i>	141
<i>Human data on radiosensitivity and tumorigenesis</i>	145
<i>The Population Modeling of Radiation Cancer Risk: Impact of Strongly Expressing Genetic Disorders</i>	147
<i>Genes of Low Penetrance</i>	148
<i>Conclusions</i>	152
SUMMARY.....	154
<i>Mechanisms of radiation tumorigenesis</i>	154

<i>Quantitative studies of experimental tumorigenesis</i>	155
<i>Genetic susceptibility to radiation-induced cancer</i>	155
4 HERITABLE GENETIC EFFECTS OF RADIATION IN HUMAN POPULATIONS	157
INTRODUCTION AND BRIEF HISTORY	157
GENERAL FRAMEWORK	158
<i>Goal of genetic risk estimation</i>	158
GENETIC DISEASES.....	159
<i>Mendelian diseases</i>	159
<i>Multifactorial diseases</i>	160
<i>Chromosomal diseases</i>	161
RISK ESTIMATION METHODS.....	161
<i>The doubling dose method</i>	161
<i>Risk estimation for the different classes of genetic disease</i>	162
<i>The concept of mutation component</i>	162
RECENT ADVANCES WITH RESPECT TO THE THREE QUANTITIES USED WITH THE DD METHOD OF RISK ESTIMATION	163
<i>Baseline frequencies of genetic diseases</i>	163
<i>The doubling dose</i>	166
<i>The incorrectness of the assumption of similarity of spontaneous mutation rates in mice and humans and the need to revert to the use of human spontaneous mutation rates for DD calculations</i>	167
<i>Doubling dose estimation using spontaneous mutation rates of human genes and induced rates of mouse genes</i>	169
THE DOUBLING DOSE ESTIMATE.....	178
MUTATION COMPONENT OF GENETIC DISEASES	178
<i>Background</i>	178
<i>Estimation of MC</i>	181
MC ESTIMATION FOR CHRONIC MULTIFACTORIAL DISEASE.....	186
<i>Introduction</i>	186
<i>The Finite-Locus-Threshold Model (FLTM)</i>	186
<i>Bridging the gap between rates of radiation-induced mutations in mice and the risk of inducible genetic diseases in humans</i>	192
<i>The potential ‘disease phenotypes’ of radiation-induced genetic damage in humans</i>	197
OTHER POTENTIALLY RELEVANT DATA	199
<i>Induction of mutations at expanded simple tandem repeat (ESTR) loci in the mouse and minisatellite loci in human germ cells</i>	199
RISK ESTIMATION.....	202
<i>Introduction</i>	202
<i>Summary of advances since the 1990 BEIR V report</i>	202
<i>Current risk estimates</i>	204
<i>Comparisons of the present estimates with those in the 1990 BEIR V Report</i>	207
<i>Reconciliation of the present estimates with the main conclusions of the genetic studies on A-bomb survivors in Japan</i>	207
<i>Strengths and weaknesses of the risk estimates presented in this document</i>	209
ANNEX 4-A MODELS OF INHERITANCE OF MULTIFACTORIAL DISEASES IN THE POPULATION	212
<i>Models of inheritance of multifactorial diseases in the population</i>	212
ANNEX 4-B THE DOUBLING DOSE	217
ANNEX 4-C ASSUMPTIONS AND SPECIFICATIONS OF THE FINITE-LOCUS THRESHOLD MODEL.....	221
<i>Assumptions and specifications of the Finite-Locus Threshold Model (FLTM) of disease liability that is used for estimating mutation component of chronic diseases</i>	221
ANNEX 4-D DIFFERENCES BETWEEN SPONTANEOUS DISEASE-CAUSING MUTATIONS IN HUMANS AND RADIATION-INDUCED MUTATIONS IN EXPERIMENTAL SYSTEMS	222
ANNEX 4-E THE CRITERIA USED TO ASSIGN HUMAN GENES INTO ONE OF THREE GROUPS FROM THE STANDPOINT OF THE RECOVERABILITY OF INDUCED MUTATIONS IN LIVE BIRTHS.	223
ANNEX 4-F RADIATION STUDIES WITH EXPANDED SIMPLE TANDEM REPEAT (ESTR) LOCI IN THE MOUSE AND MINISATELLITE LOCI IN HUMAN GERM CELLS	224

<i>Introduction</i>	224
<i>Mouse ESTRs</i>	224
<i>Human minisatellites</i>	224
<i>Radiation studies with mouse ESTR loci</i>	225
<i>Radiation-induced mutations at human minisatellite loci</i>	227
ANNEX 4-G DOUBLING DOSE (DD) ESTIMATES ESTIMATED FROM THE GENETIC DATA OF THE CHILDREN OF A-BOMB SURVIVORS	233
5 BACKGROUND FOR EPIDEMIOLOGIC METHODS	235
INTRODUCTION	235
COLLECTION OF EPIDEMIOLOGIC DATA	236
<i>Types of Epidemiologic Studies</i>	237
<i>Randomized Intervention Trials</i>	237
<i>Cohort Studies</i>	238
<i>Case-control studies</i>	239
<i>Comparability in Study Design</i>	240
<i>Statistical Power</i>	242
ANALYSIS OF EPIDEMIOLOGIC DATA	242
<i>Measures of Association</i>	243
<i>Tools of Statistical Inference</i>	244
<i>Control of Confounding</i>	245
<i>The Linear Relative Risk Model</i>	245
INTERPRETATION OF EPIDEMIOLOGIC DATA	246
<i>Assessment of Associations</i>	246
<i>Assessment of Dose-Response Relationships</i>	249
6 A-BOMB SURVIVOR STUDIES	250
INTRODUCTION	250
DESCRIPTION OF THE COHORT	251
<i>Health Endpoint Data</i>	251
<i>Dosimetry</i>	252
STATISTICAL METHODS	253
<i>Leukemia</i>	254
ALL SOLID CANCERS	255
<i>Additional analyses addressing the shape of the dose-response function</i>	257
<i>Other analyses</i>	258
SITE-SPECIFIC CANCERS	259
<i>Female breast cancer</i>	263
<i>Thyroid cancer</i>	263
<i>Salivary gland cancer</i>	264
<i>Stomach cancer</i>	264
<i>Liver cancer</i>	264
<i>Lung cancer</i>	265
<i>Skin cancer</i>	266
<i>Central nervous system cancers</i>	266
<i>Lymphoma</i>	266
<i>Multiple myeloma</i>	266
CANCERS RESULTING FROM EXPOSURE <i>IN UTERO</i>	266
BENIGN NEOPLASMS	267
NON-NEOPLASTIC DISEASE	268
<i>Findings based on mortality data</i>	268
<i>Findings based on the Adult Health Study (AHS) or on autopsy data</i>	269
LIFE SHORTENING	270
SUMMARY OF A-BOMB SURVIVOR CHAPTER	271
7 MEDICAL RADIATION STUDIES	273

Prepublication copy Uncorrected Proofs

INTRODUCTION.....	273
MEDICAL USES OF RADIATION	274
<i>Radiotherapy for malignant disease.....</i>	276
<i>Radiotherapy for benign disease among adults</i>	285
<i>Radiotherapy for benign disease among children.....</i>	291
<i>Diagnostic radiation among adults.....</i>	297
<i>Diagnostic radiation among children.....</i>	301
EVALUATION OF RISK FOR SPECIFIC CANCER SITES	303
<i>Lung Cancer.....</i>	304
<i>Female breast cancer.....</i>	307
<i>Thyroid cancer.....</i>	316
<i>Leukemia.....</i>	319
<i>Stomach Cancer.....</i>	324
<i>Radiation and circulatory diseases</i>	327
DISCUSSION.....	327
SUMMARY	328
8 OCCUPATIONAL RADIATION STUDIES.....	331
INTRODUCTION.....	331
NUCLEAR INDUSTRY WORKERS	332
<i>Principal references</i>	332
<i>Characteristics of studies of nuclear industry workers</i>	336
<i>Assessment of exposure to radiation</i>	341
<i>Results.....</i>	342
<i>Design issues</i>	352
<i>Adequacy of the dose estimates</i>	352
<i>Possible confounding and modifying factors.....</i>	354
WORKERS FROM THE MAYAK FACILITY	357
CHERNOBYL CLEAN-UP WORKERS	358
<i>Follow-up</i>	360
<i>Radiation doses to different groups: dose levels and available estimates.....</i>	361
<i>Results.....</i>	361
AIRLINE AND AEROSPACE EMPLOYEES	362
MEDICAL AND DENTAL OCCUPATIONAL EXPOSURES	363
SUMMARY	364
9 ENVIRONMENTAL RADIATION STUDIES	366
INTRODUCTION.....	366
POPULATIONS LIVING AROUND NUCLEAR FACILITIES.....	368
POPULATIONS EXPOSED FROM ATMOSPHERIC TESTING, FALLOUT, OR OTHER ENVIRONMENTAL RELEASE OF RADIATION	374
POPULATIONS EXPOSED FROM THE CHERNOBYL ACCIDENT.....	381
<i>Thyroid Cancer.....</i>	392
<i>Leukemia.....</i>	396
<i>Solid Tumors Other Than Thyroid Cancer.....</i>	399
POPULATIONS EXPOSED FROM NATURAL BACKGROUND.....	400
CHILDREN OF ADULTS EXPOSED TO RADIATION	402
EXPOSURE TO RADIOACTIVE IODINE ¹³¹ I	412
DISCUSSION.....	414
SUMMARY	418
10 INTEGRATION OF BIOLOGY AND EPIDEMIOLOGY.....	421
INTRODUCTION.....	421
DNA DAMAGE RESPONSE AND CANCER RISK.....	421
PROJECTION OF RISKS OVER TIME	422

Prepublication copy Uncorrected Proofs

THE TRANSPORT OF CANCER RISK BETWEEN DIFFERENT POPULATIONS.....	423
<i>Post-irradiation Cancer Mechanisms and Choice of Transport Model</i>	424
<i>The etiology of cancer at different sites</i>	425
<i>Stomach cancer</i>	425
<i>Breast cancer</i>	427
<i>Thyroid cancer</i>	428
<i>Leukemia</i>	429
THE FORM OF THE DOSE-RESPONSE FOR RADIATION TUMORIGENESIS.....	430
DOSE AND DOSE-RATE EFFECTS ON TUMOR INDUCTION.....	432
<i>Derivation of the dose and dose rate reduction factor by Bayesian Analysis</i>	433
OTHER FORMS OF CELLULAR AND ANIMAL RESPONSE TO RADIATION.....	439
<i>Adaptive responses</i>	439
<i>Induced genomic instability</i>	440
<i>Bystander cellular effects</i>	440
GENETIC SUSCEPTIBILITY TO CANCER.....	441
HERITABLE EFFECTS OF RADIATION.....	441
SUMMARY.....	443
ANNEX 10-A APPLICATION OF THE MOOLGAVKAR AND KNUDSON 2-STAGE CLONAL EXPANSION MODEL TO THE TRANSPORT OF RADIATION.....	445
CANCER RISK.....	445
ANNEX 10-B EVIDENCE FOR THE CONNECTION BETWEEN DOSE EFFECTS AND DOSE RATE EFFECTS IN ANIMAL EXPERIMENTS.....	447
DETAILS OF DDREF ESTIMATION.....	449
11 RISK ASSESSMENT, MODELS AND METHODS.....	455
RISK ASSESSMENT METHODOLOGY.....	455
<i>Rates, Risks, and Probability Models</i>	455
<i>Incidence Rates and Excess Risks</i>	458
RISK MODELS.....	459
<i>Direct Estimates of Risk</i>	459
<i>Estimation via Mathematical Models for Risk</i>	460
<i>Biologically-Based Risk Models</i>	460
<i>Empirically-Based Risk Models</i>	462
VARIABLES THAT MODIFY THE DOSE-RESPONSE RELATIONSHIP.....	464
<i>Model Parameter Estimation</i>	464
<i>Using the Estimated Model</i>	465
<i>Modeling Caveats</i>	466
<i>Estimated Doses</i>	467
12 ESTIMATING CANCER RISK.....	470
INTRODUCTION.....	470
DATA EVALUATED FOR BEIR VII MODELS.....	470
MEASURES OF RISK AND CHOICE OF CANCER ENDPOINTS.....	471
THE BEIR VII COMMITTEE'S PREFERRED MODELS.....	473
<i>Approach to Analyses</i>	473
<i>Models for All Solid Cancers</i>	474
<i>Models for Site-Specific Solid Cancers Other Than Breast and Thyroid</i>	477
<i>Models for female breast cancer</i>	479
<i>Model for thyroid cancer</i>	480
<i>Model for Leukemia</i>	480
USE OF THE COMMITTEE'S PREFERRED MODELS TO ESTIMATE RISKS FOR THE U.S. POPULATION.....	483
<i>Estimating risks from exposure to low doses and low dose rates</i>	483
<i>Projection of risks over time</i>	483
<i>Transport of Risks From a Japanese to a US Population</i>	484
<i>Relative effectiveness of x rays and γ rays</i>	485

<i>Relative effectiveness of internal exposure</i>	486
<i>Method of calculating lifetime risks</i>	486
QUANTITATIVE EVALUATION OF UNCERTAINTY IN LIFETIME RISKS	488
RESULTS OF RISK CALCULATIONS.....	489
<i>Lifetime risk estimates for the US population</i>	489
<i>Comparison of BEIR VII Risk Estimates with Those from Other Sources</i>	496
UNCERTAINTIES IN LIFETIME RISK ESTIMATES	499
<i>Quantitative evaluation of uncertainty</i>	499
<i>Sources of Uncertainty Not Included in the Quantitative Assessment</i>	502
COHERENCE OF MODELS WITH OTHER STUDIES.....	504
<i>Comparison with studies of persons exposed for medical reasons</i>	504
<i>Comparison with studies of nuclear workers exposed at low doses and dose rates</i>	509
SUMMARY	510
ANNEX 12 A. PREVIOUS MODELS FOR ESTIMATING CANCER RISKS FROM EXPOSURE TO LOW LEVELS OF LOW-LET IONIZING RADIATION	513
BEIR V	513
ICRP	514
NCRP.....	515
EPA	515
UNSCEAR	516
NIH RADIOEPIDEMIOLOGIC TABLES.....	518
ANNEX 12 B. COMMITTEE ANALYSES OF DATA ON THE LSS COHORT TO DEVELOP BEIR VII MODELS FOR ESTIMATING CANCER RISKS	521
<i>Approach to analyses</i>	521
<i>General considerations in describing dependencies of solid cancer risks on exposure age and attained age</i>	522
<i>Analyses of incidence data on all solid cancers excluding thyroid and non-melanoma skin cancer and of mortality data on all solid cancers</i>	524
<i>Analyses of incidence and mortality data on site-specific solid cancers</i>	534
<i>Analyses of data on leukemia</i>	541
ANNEX 12 C. DETAILS OF LAR UNCERTAINTY ANALYSIS	545
<i>Uncertainty Due to Sampling Variability</i>	545
<i>Combining several sources of uncertainty</i>	546
ANNEX 12 D. ADDITIONAL EXAMPLES OF LIFETIME RISK ESTIMATES BASED ON BEIR VII PREFERRED MODELS.....	549
13 SUMMARY AND RESEARCH NEEDS.....	553
EVIDENCE FROM BIOLOGY	553
<i>Molecular and cellular responses to ionizing radiation</i>	553
<i>Consideration of phenomena that might affect risk estimates for carcinogenesis at very low doses</i>	554
GENETIC EFFECTS OF RADIATION ON HUMAN POPULATIONS	558
<i>Revision of the conceptual basis for calculating the DD</i>	559
<i>Revision of the baseline frequencies of Mendelian diseases in humans</i>	559
<i>Delineation of a new concept – the concept of potential recoverability correction factor</i>	559
<i>Introduction of the concept that the adverse hereditary effects of radiation are likely to be manifest as multi- system developmental abnormalities</i>	560
EPIDEMIOLOGIC STUDIES OF POPULATIONS EXPOSED TO IONIZING RADIATION	561
<i>A-bomb survivor studies</i>	561
<i>Medical radiation studies</i>	563
<i>Occupational radiation studies</i>	565
<i>Environmental radiation studies</i>	566
INTEGRATION OF BIOLOGY AND EPIDEMIOLOGY	567
MODELS FOR ESTIMATING THE LIFETIME RISK OF CANCER.....	568
CONCLUSION	571
APPENDICES.....	572
APPENDIX A	573

Prepublication copy Uncorrected Proofs

BASIC BIOLOGICAL AND GENETIC CONCEPTS.....	573
<i>DNA, Genes, and Chromosomes</i>	573
<i>Mutations and Their Effects on the Phenotype</i>	574
<i>Genetic Diseases</i>	574
<i>Genetic Effects of Radiation</i>	575
APPENDIX B.....	576
COMMENTARY ON “RADIATION FROM MEDICAL PROCEDURES IN THE PATHOGENESIS OF CANCER AND ISCHEMIC HEART DISEASE: DOSE-RESPONSE STUDIES WITH PHYSICIANS PER 100,000 POPULATION”	576
<i>Comment</i>	576
<i>Summary</i>	576
APPENDIX C	577
ISSUES RAISED BY THE INSTITUTE FOR ENERGY AND ENVIRONMENT	577
RESEARCH (IEER).....	577
1. <i>Effects of radionuclides that cross the placenta</i>	577
2. <i>Effects of radiation on female fetuses</i>	577
3. <i>Effects of organically-bound radionuclides</i>	577
4. <i>Synergistic effects</i>	578
5. <i>Data integrity and quality</i>	578
6. <i>Effects on various populations</i>	578
APPENDIX D	579
HORMESIS	579
<i>Theoretical considerations</i>	579
<i>Evidence from Cell biology</i>	580
<i>Adaptive response</i>	580
<i>Evidence from Animal experiments</i>	582
HORMESIS AND EPIDEMIOLOGY	583
<i>Summary</i>	585
APPENDIX E.....	586
15-COUNTRY WORKERS STUDY	586
GLOSSARY	587
COMMITTEE BIOGRAPHIES	595
REFERENCES CITED.....	602